

صندوق الأهلي العالمي للرعاية الصحية
SNB Capital Global Helth Care Fund

التقرير السنوي 2022
Annual Report 2022



Contents**المحتويات****A) Investment Fund Information****أ) معلومات صندوق الاستثمار****B) Fund Performance****ب) أداء الصندوق****C) Fund Manager****ج) مدير الصندوق****D) Custodian****د) أمين الحفظ****E) Fund Operator****هـ) مشغل الصندوق****F) Auditor****و) مراجع الحسابات****G) Financial Statements****ز) القوائم المالية****Annex – Exercised Voting Rights****ملحق – ممارسات التصويت السنوية**

A) Investment Fund Information
أ) معلومات صندوق الاستثمار

1) Name of the Investment Fund SNB Capital Global Health Care Fund	1) اسم صندوق الاستثمار صندوق الأهلي العالمي للرعاية الصحية
2) Investment Objectives and Policies <ul style="list-style-type: none"> Fund's Objectives: The Fund aims to achieve medium to long term capital growth by investing in globally listed equities of health care companies according to the Sharia Guidelines. Investment Policies and Practices: The Fund invests mainly in shares of listed companies and concentrates its investments in shares of companies providing healthcare services and related activities. 	2) أهداف وسياسات الاستثمار وممارساته <ul style="list-style-type: none"> أهداف الصندوق: يهدف الصندوق إلى نمو رأس المال على المدى المتوسط إلى الطويل من خلال الاستثمار في أسهم شركات الرعاية الصحية المدرجة عالمياً وفقاً للضوابط الشرعية. سياسات الاستثمار وممارساته: يستثمر الصندوق بشكل أساسي في أسهم الشركات المدرجة ويركز استثماراته في أسهم شركات تقدم خدمات الرعاية الصحية والأنشطة ذات الصلة.
3) Distribution of Income & Gain Policy Income and dividends will be reinvested in the Fund. No income or dividends will be distributed to Unitholders.	3) سياسة توزيع الدخل والأرباح يتم إعادة استثمار الدخل والأرباح في الصندوق، ولا يتم توزيع أي دخل وأرباح على مالكي الوحدات.
4) The fund's reports are available upon request free of charge.	4) تتاح تقارير الصندوق عند الطلب وبدون مقابل.
5) The fund's benchmark and the service provider's website (if any) MSCI World Healthcare Islamic M-Series (Net Total Return Index). The benchmark service and its data are provided by (MSCI Inc.).	5) المؤشر الاسترشادي للصندوق، والموقع الإلكتروني لمزود الخدمة (إن وجد) مؤشر "إم إس سي آي" الإسلامي العالمي للرعاية الصحية من الفئة "إم" (صافي العائد الإجمالي بالدولار الأمريكي). ويتم تزويد خدمة المؤشر وبياناته عن طريق (MSCI Inc.).

B) Fund Performance

أداء الصندوق

- 1) A comparative table covering the last three financial years/or since inception, highlighting: جدول مقارنة يغطي السنوات المالية الثلاث الأخيرة/ أو منذ التأسيس، يوضح:

Year	2022	2021	2020	السنة
NAV*	60,183,000	81,772,383	72,586,537	صافي قيمة أصول الصندوق*
NAV per Unit*	3.19	3.66	3.15	صافي قيمة أصول الصندوق لكل وحدة*
Highest Price per Unit*	3.61	3.67	3.15	أعلى سعر وحدة*
Lowest Price per Unit *	2.77	3.01	2.11	أقل سعر وحدة*
Number of Units	18,881,000	22,314,096	22,176,864	عدد الوحدات
Income Distribution Per Unit	N/A	N/A	N/A	قيمة الأرباح الموزعة لكل وحدة
Fees & Expense Ratio	2.22%	2.18%	2.19%	نسبة الرسوم والمصروفات
Percentage of borrowed assets from the total asset value, the period of their exposure period and due date (if any)	N/A	N/A	N/A	نسبة الأصول المقرضة من إجمالي قيمة الأصول، ومدة انكشافها وتاريخ استحقاقها (إن وجدت)

*In US Dollar

*بالدولار الأمريكي

- 2) A performance record that covers the following: سجل أداء يغطي ما يلي:

- a. The total return for the fund compared to the benchmark for 1 year, 3 years, 5 years and since inception: أ. العائد الإجمالي للصندوق مقارنة بالمؤشر لسنة واحدة، ثلاث سنوات، خمس سنوات ومنذ التأسيس:

Period	Since Inception منذ التأسيس	5 Years 5 سنوات	3 Years 3 سنوات	1 Year سنة	الفترة
Return %	5.37	7.38	5.52	-13.02	عائد الصندوق %
Benchmark %	7.08	10.31	7.76	-8.99	عائد المؤشر %

- b. The annual total return for the fund compared to the benchmark for the last 10 years/ or since inception: ب. العائد الإجمالي السنوي للصندوق مقارنة بالمؤشر للعشر سنوات الماضية/ أو منذ التأسيس:

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	السنة
Return %	-13.02	16.33	16.12	21.56	-0.05	14.07	-12.34	4.44	16.30	34.89	عائد الصندوق %
Benchmark %	-8.99	17.51	16.99	26.62	3.09	17.78	-7.50	6.82	16.54	36.52	عائد المؤشر %

c. Actual fees and fund expenses paid by the investment fund during the year as a percentage of average Net Asset Value:

ج. مقابل الخدمات والعمولات والأتعاب التي تحملها الصندوق على مدار العام كنسبة مئوية من متوسط صافي قيمة أصول الصندوق:

Fees and Expenses	ألف دولار USD'000	النسبة المئوية %	الرسوم والمصروفات
Management Fees	1,204	1.85%	أتعاب الإدارة
VAT on Management Fees	180	0.28%	ضريبة القيمة المضافة على أتعاب الإدارة
Custodian Fees	14	0.02%	رسوم الحفظ
Auditor Fees	10	0.02%	أتعاب مراجع الحسابات
Fund Admin Expenses	16	0.03%	مصاريف العمليات الإدارية
CMA Fees	2	0.00%	رسوم هيئة السوق المالية
Tadawul Fees	0	0.00%	رسوم نشر معلومات الصندوق على موقع تداول
Shariah Committee Fees	8	0.01%	أتعاب خدمات اللجنة الشرعية
Independent Fund Board Remunerations	6	0.01%	مكافآت أعضاء مجلس إدارة الصندوق المستقلين
Total Fees and Expenses	1,440	2.22%	مجموع الرسوم والمصاريف

3) Material Changes

There were no material changes that occurred during the period.

3) تغيرات جوهرية حدثت خلال الفترة

لم تحدث أي تغييرات جوهرية تؤثر على أداء الصندوق خلال الفترة.

4) Exercising of Voting Rights

The Fund Manager has exercised voting rights, for more details kindly refer to the "Exercising of voting right Annex".

4) ممارسات التصويت السنوية

قام مدير الصندوق بممارسات التصويت السنوية. و للمزيد من التفاصيل يرجى مراجعة "ملحق ممارسات التصويت السنوية".

5) Fund Board Annual Report

5) تقرير مجلس إدارة الصندوق السنوي

a. Names of Fund Board Members

- Naif Al Saif – Chairman – Non-Independent Member
- Wisam Fasihaldin - Non-Independent Member
- Dr. Asem Al Homaidi - Independent Member
- Mohammed Al Oyaidi - Independent Member

أ. أسماء أعضاء مجلس إدارة الصندوق

- نايف آل سيف - رئيس مجلس إدارة الصندوق - عضو غير مستقل
- وسام فصيح الدين - عضو غير مستقل
- د. عاصم الحميضي - عضو مستقل
- محمد العبيدي - عضو مستقل

b. A brief about the fund board members' qualifications

Naif Al-Saif: He is currently the Head of Principal Investments in SNB Capital. Naif joined Samba in February 2006. He has 15 years of experience. In Samba, Naif has managed the fixed income portfolio of more than SAR 60 billion and managed the public budget of SAR 225 billion. He is also the Chief Operating Officer in Samba London. Moreover, he is a member in Samba's Asset and Liability Committee. He has taken part in several strategic projects in developing the Saudi banking sector. Prior to joining Samba, he worked for Saudi Hollandi Bank, Derivatives Department, Treasury Section. Naif holds a bachelor's degree with Honors in Finance and Economics from

ب. نبذة عن مؤهلات أعضاء مجلس إدارة الصندوق

نايف آل سيف: رئيس إدارة الاستثمارات الخاصة لدى شركة الأهلي المالية. انضم نايف إلى سامبا في فبراير 2006 حاصل على 15 سنة من الخبرة في العمل في سامبا، تولى نايف إدارة محفظة الدخل الثابت والتي تتجاوز 60 مليار ريال سعودي، بالإضافة إلى إدارة الميزانية العمومية التي تتجاوز 225 مليار ريال سعودي. وهو أيضاً رئيس المتداولين لفرع سامبا لندن. وهو عضو في لجنة الأصول والخصوم في سامبا. وقد شارك في العديد من المشاريع الاستراتيجية في تطوير القطاع المصرفي السعودي. قبل انضمامه إلى سامبا، عمل في البنك السعودي الهولندي، قسم المشتقات المالية - إدارة الخزينة. حصل نايف على درجة البكالوريوس في العلوم المالية والاقتصاد من جامعة الملك فهد للبترول والمعادن وشهادة الماجستير في إدارة الأعمال / مالية من جامعة الأمير سلطان بمرتبة الشرف.

King Fahd University of Petroleum and Minerals and MBA from Prince Sultan University.

Wisam Fasihaldin: He is the Chief Financial Officer at Jeddah Central Development Company (A subsidiary of PIF). Also, he was the Chief Financial Officer at SNB Capital. He joined SNB Capital in 2014G. Prior to that he held multiple roles at Saudi National Bank. He has more than 20 years of experience in financial sector. He received an MBA degree - specialized in Finance University of Business & Technology (former CBA). He holds a Bachelor degree - specialized in Business Administration from King Abdulaziz University.

Dr. Asem Al Homaidi: He is an assistant professor of Finance and Investment. He received PhD in Finance from the University of New Orleans in United States of America, a Master in Financial Economics from University of New Orleans in United States of America, a Master of Finance from University of Tampa, FL and Bachelor's degree from King Saud University in Business Administration (major in Finance) Excellent grade with First Class Honor.

Mohammed Al Oyaidi: He is the founder of OCPAs, has more than 15 years of experience in the area of capital markets, accounting, auditing and risk management. He has also worked in some international companies and agencies such as KPMG, Ernst & Young, the World Bank Group and the Saudi Capital Market Authority. He received a Master of Business Administration from Oklahoma City University and a Bachelor's degree in Accounting from King Saud University. He was awarded CPA Fellowship as well as SOCPA Fellowship. Aloyaidi is Business Valuer certified by Saudi Authority for Accredited Valuers (TAQEEM).

c. Roles and responsibilities of the Fund Board

The responsibilities of the members of the fund board shall include the following:

1. Approving material contracts, decisions and reports involving the fund.
2. Approve a written policy in regards to the voting rights related to the fund assets.
3. Overseeing and, where appropriate, approving or ratifying any conflicts of interest the fund manager has identified.
4. Meeting at least twice annually with the fund manager's compliance committee or its compliance officer to review the fund manager's compliance with all applicable rules, laws and regulations.
5. Approving all changes stipulated in Articles (62) and (63) of the Investment Funds Regulations "IFRs" before the fund manager obtains the approval or notification of the unitholders and the Authority (as applicable).
6. Confirming the completeness and accuracy (complete, clear, accurate, and not misleading), and compliance with the IFRs, of the Terms and Conditions and of any other document, contractual or otherwise.

وسام فصيح الدين: المدير المالي لشركة وسط جدة للتطوير (إحدى الشركات التابعة لصندوق الاستثمارات العامة). شغل سابقاً منصب المدير المالي في شركة الأهلي المالية. انضم إلى شركة الأهلي المالية عام 2014م. شغل عدة مناصب في البنك الأهلي السعودي. لديه أكثر من 20 عاماً من الخبرة في الإدارة المالية. حاصل على ماجستير في إدارة الأعمال من جامعة الأعمال والتكنولوجيا في المملكة العربية السعودية، وشهادة مراقب تكاليف معتمد. وحاصل على درجة البكالوريوس في إدارة الأعمال من جامعة الملك عبدالعزيز.

د. عاصم الحميضي: الدكتور عاصم، أستاذ المالية والاستثمار المساعد. حصل على درجة الدكتوراه في الفلسفة المالية من جامعة نيو أورلينز في الولايات المتحدة الأمريكية، ودرجة الماجستير في الاقتصاد المالي من جامعة نيو أورلينز ومن جامعة تامبا في الولايات المتحدة الأمريكية، ودرجة الماجستير في العلوم المالية من جامعة تامبا في الولايات المتحدة الأمريكية. درس في جامعة الملك سعود وحصل على درجة البكالوريوس في إدارة الأعمال (تخصص المالية) بتقدير امتياز مع مرتبة الشرف الأولى.

محمد العبيدي: مؤسس مكتب العبيدي محاسبون ومراجعون قانونيون، يمتلك خبرة أكثر من (15) عام في السوق المالية والمحاسبة والمراجعة وإدارة المخاطر. سبق له العمل في بعض بيوت الخبرة العالمية مثل شركة كي بي إم جي (KPMG)، وارنست آند يونغ (Ernst & Young)، والبنك الدولي، وهيئة السوق المالية السعودية. حصل على ماجستير إدارة أعمال من جامعة مدينة أوكلاهوما، وشهادة البكالوريوس في المحاسبة من جامعة الملك سعود وزمالة المحاسبين القانونيين الأمريكية (CPA)، وزمالة الهيئة السعودية للمحاسبين القانونيين (SOCPA)، وهو مقيم منشآت معتمد لدى الهيئة السعودية للمقيمين المعتمدين.

ج. أدوار مجلس إدارة الصندوق ومسؤولياته

تشمل مسؤوليات أعضاء مجلس إدارة الصندوق، على سبيل المثال لا الحصر، الآتي:

1. الموافقة على جميع العقود والقرارات والتقارير الجوهرية التي يكون الصندوق طرفاً فيها.
2. اعتماد سياسة مكتوبة فيما يتعلق بحقوق التصويت المتعلقة بأصول الصندوق.
3. الإشراف، ومتى كان ذلك مناسباً، الموافقة أو المصادقة على أي تعارض مصالح يفصح عنه مدير الصندوق وفقاً لللائحة صناديق الاستثمار.
4. الاجتماع مرتين سنوياً على الأقل مع لجنة المطابقة والالتزام لدى مدير الصندوق أو مسؤول المطابقة والالتزام لديه، للتأكد من التزام مدير الصندوق بجميع اللوائح والأنظمة المتبعة.
5. الموافقة على جميع التغييرات المنصوص عليها في المادتين (62) و (63) من لائحة صناديق الاستثمار وذلك قبل حصول مدير الصندوق على موافقة مالكي الوحدات والهيئة أو إشارتهم (حيثما ينطبق).
6. التأكد من اكتمال ودقة شروط وأحكام الصندوق وأي مستند آخر (سواء أكان عقداً أم غيره) يتضمن إفصاحات تتعلق بالصندوق ومدير الصندوق

7. Ensuring that the fund manager carries out its obligations in the best interests of the unitholders, in accordance with the IFRs and the Fund's Terms and Conditions.
8. Reviewing the report that includes assessment of the performance and quality of services provided by the parties involved in providing significant services to the fund referred to in Paragraph (l) of Article (9) of IFRs, in order to ensure that the fund manager fulfils his responsibilities in the interest of unitholders in accordance with the Fund's Terms and Conditions and the provisions stipulated in IFRs.
9. Assessing the mechanism of the fund manager's handling of the risks related to the fund's assets in accordance with the fund manager's policies and procedures that detect the fund's risks and how to treat such risks.
10. Have a fiduciary duty to unitholders, including a duty to act in good faith, a duty to act in the best interests of the unitholders and a duty to exercise all reasonable care and skill.
11. Approving the appointment of the external Auditor nominated by the Fund Manager.
12. Taking minutes of meetings that provide all deliberations and facts of the meetings and the decisions taken by the fund's board of director.
13. Review the report containing all complaints and the measures taken regarding them referred to in Paragraph (m) of Article (9) of IFRs, in order to ensure that the fund manager carries out his responsibilities in a way that serves the interest of unitholders in accordance with the Fund's Terms and Conditions and what contained in this Regulation.

d. Remuneration of fund board members

Each member of the Fund's independent Board of Directors receives USD (37,333.33) annually, divided by the number of open-ended public investment funds managed by the Fund Manager and supervised by the Fund Board.

e. A statement of any conflict or potential conflict of interest between the interests of a fund board member and the interests of the fund

Members of the Fund Board may be members of other funds that may seek investment objectives similar to those of the Fund. Therefore, in the exercise of its business, a member of the Fund Board may find himself in a situation of potential conflict of duties or interests with one or more funds. However, in such cases, the member shall take into account his obligations to act in the best interests of the Unitholders to the maximum practicable extent and not to overlook his obligations to his other clients when he considers any investment that may involve a potential conflict of interest, and in situations requiring voting, that Member shall refrain from doing so. To the date of issuing the Terms and Conditions, there is no significant business or other interest to the

وإدارته للصندوق، إضافةً إلى التأكد من توافق ما سبق مع أحكام لائحة صناديق الاستثمار.

7. التأكد من قيام مدير الصندوق بمسؤولياته بما يحقق مصلحة مالي الوحدات وفقاً لشروط وأحكام الصندوق، وأحكام لائحة صناديق الاستثمار.
8. الاطلاع على التقرير المتضمن تقييم أداء وجودة الخدمات المقدمة من الأطراف المعنية بتقديم الخدمات الجوهرية للصندوق المشار إليه في الفقرة (ل) من المادة (9) من لائحة صناديق الاستثمار؛ وذلك للتأكد من قيام مدير الصندوق بمسؤولياته بما يحقق مصلحة مالك الوحدات وفقاً لشروط وأحكام الصندوق وما ورد في لائحة صناديق الاستثمار.
9. تقييم آلية تعامل مدير الصندوق مع المخاطر المتعلقة بأصول الصندوق وفقاً لسياسات وإجراءات مدير الصندوق حيال رصد المخاطر المتعلقة بالصندوق وكيفية التعامل معها.
10. العمل بأمانة وحسن نية واهتمام ومهارة وعناية وحرص وبما يحقق مصلحة مالي الوحدات.
11. الموافقة على تعيين مراجع الحسابات بعد ترشيحه من قبل مدير الصندوق.
12. تدوين محاضر الاجتماعات التي تشتمل على جميع وقائع الاجتماعات والقرارات التي اتخذها مجلس إدارة الصندوق.
13. الاطلاع على التقرير المتضمن جميع الشكاوى والإجراءات المتخذة حيالها المشار إليه في الفقرة (م) من المادة (9) من لائحة صناديق الاستثمار؛ وذلك للتأكد من قيام مدير الصندوق بمسؤولياته بما يحقق مصلحة مالي الوحدات وفقاً لشروط وأحكام الصندوق وما ورد في لائحة صناديق الاستثمار.

د. مكافآت أعضاء مجلس إدارة الصندوق

يتقاضى عضو مجلس إدارة الصندوق المستقل (37,333.33) دولار سنوياً مقسمة على عدد الصناديق العامة المفتوحة المدارة من قبل مدير الصندوق والتي يشرف عليها المجلس.

هـ. تعارض المصالح بين مصالح عضو مجلس إدارة الصندوق

ومصالح الصندوق

يجوز لأعضاء مجلس إدارة الصندوق أن يكونوا أعضاء من حين لآخر لصناديق أخرى قد تنشأ أهدافاً استثمارية مماثلة لتلك الخاصة بالصندوق. ولذلك، فمن الممكن أن يجد أحد أعضاء مجلس إدارة الصندوق، في نطاق ممارسته لأعماله، أنه في موقف ينطوي على تعارض محتمل في الواجبات أو المصالح مع واحد أو أكثر من الصناديق. وعلى أي حال، ففي تلك الحالات سوف يراعي عضو مجلس الإدارة التزاماته بالتصرف بما يحقق أقصى مصالح مالي الوحدات المعنيين إلى أقصى درجة ممكنة عملياً، وعدم إغفال التزاماته تجاه عملائه الآخرين عند الاطلاع بأي استثمار قد ينطوي على تعارض محتمل في المصالح، وفي الحالات التي تتطلب التصويت سوف يمتنع ذلك العضو عن ذلك. علماً أنه إلى تاريخ إعداد الشروط والأحكام، لا يوجد أي نشاط عمل أو مصلحة أخرى مهمة لأعضاء

members of the Fund Board, which is likely to conflict with the interests of the Fund. مجلس إدارة الصندوق أو أعضاء مجلس إدارة الصندوق يُحتمل تعارضها مع مصالح الصندوق.

f. A statement showing all the funds boards that the relevant board member is participating in و. جدول يوضح جميع مجالس إدارة الصناديق التي يشارك فيها عضو مجلس الصندوق

Fund's/ Member's Name	محمد العبيدي Mohammed Al Oyaidi	د. عاصم الحميضي Dr. Asem AlHomaidi	وسام فصيح الدين Wisam Fasihaldin	نايف آل سيف Naif Al-Saif	اسم الصندوق / العضو
SNB Capital Saudi Trading Equity Fund	✓	✓	✓	✓	صندوق الأهلي للمتاجرة بالأسهم السعودية
SNB Capital Saudi Small and Mid-Cap Equity Fund	✓	✓	✓	✓	صندوق الأهلي لأسهم الشركات السعودية الصغيرة والمتوسطة
SNB Capital Freestyle Saudi Equity Fund	✓	✓	✓	✓	صندوق الأهلي المرن للأسهم السعودية
SNB Capital GCC Trading Equity Fund	✓	✓	✓	✓	صندوق الأهلي للمتاجرة بالأسهم الخليجية
SNB Capital GCC Growth and Income Fund	✓	✓	✓	✓	صندوق الأهلي الخليجي للنمو والدخل
SNB Capital Fund of REITs Fund	✓	✓	✓	✓	صندوق الأهلي القابض لصناديق الاستثمار العقارية المتداولة
SNB Capital North America Index Fund	✓	✓	✓	✓	صندوق الأهلي لمؤشر أسهم أمريكا الشمالية
SNB Capital Europe Index Fund	✓	✓	✓	✓	صندوق الأهلي لمؤشر أسهم أوروبا
SNB Capital Asia Pacific Index Fund	✓	✓	✓	✓	صندوق الأهلي لمؤشر أسهم آسيا والباسيفيك
SNB Capital Emerging Markets Index Fund	✓	✓	✓	✓	صندوق الأهلي لمؤشر أسهم الأسواق الناشئة
SNB Capital Global Health Care Fund	✓	✓	✓	✓	صندوق الأهلي العالمي للرعاية الصحية
SNB Capital Global REITs Fund	✓	✓	✓	✓	صندوق الأهلي العالمي للريت
SNB Capital Global Megatrends Fund	✓	✓	✓	✓	صندوق الأهلي العالمي للقطاعات الواعدة
SNB Capital Sovereign Sukuk Fund				✓	صندوق الأهلي للصكوك السيادية
AlAhli SEDCO Residential Development Fund	✓	✓			صندوق الأهلي سدكو للتطوير السكني
AlAhli REIT Fund (1)	✓				صندوق الأهلي ريت (1)
SNB Capital Real Estate Fund	✓				صندوق الأهلي العقاري
AlAhli Makkah Hospitality Fund	✓				صندوق الأهلي للضيافة بمكة المكرمة
AlAhli Real Estate Opportunistic Fund	✓	✓			صندوق الأهلي العقاري للفرص
SNB Capital Real Estate Income Fund	✓	✓			صندوق الأهلي العقاري للدخل
SNB Capital Danat AlJanob Real Estate Fund	✓	✓			صندوق الأهلي دانة الجنوب العقاري
SNB Capital AlJawhara Real Estate Fund	✓	✓			صندوق الأهلي الجوهرة العقاري

g. Topics discussed and issued resolutions, as well as the fund performance and fund achievement of its objectives

The Fund's Board of Directors held three meetings during 2022. The following is a summary of the key decisions approved and the matters discussed by the Fund's Board of Directors:

- Fund's objectives achievement and performance review.
- Risks related to the funds; including: liquidity, market, and operational risks.
- Ensuring fund's compliance to all applicable rules and regulations.

ز. الموضوعات التي تمت مناقشتها والقرارات الصادرة بشأنها بما

في ذلك أداء الصندوق وتحقيق الصندوق لأهدافه

عقد مجلس إدارة الصندوق ثلاثة اجتماعات خلال العام 2022م، وفيما يلي ملخصاً لأهم القرارات التي تم إقرارها والمواضيع التي تمت مناقشتها من قبل مجلس إدارة الصندوق:

- مناقشة تحقيق الصندوق لأهدافه وأدائه خلال العام.
- المخاطر المتعلقة بالصندوق بما في ذلك مخاطر السيولة، السوق، والتشغيل.
- التزام الصناديق بلوائح هيئة السوق المالية مع مسؤول المطابقة والالتزام.

C) Fund Manager

ج) مدير الصندوق

1) Name and address of the Fund Manager

SNB Capital Company

King Saud Road, P.O. Box 22216, Riyadh 11495, Saudi Arabia
Tel: +966 920000232

Website: www.alahlicapital.com

1) اسم مدير الصندوق، وعنوانه

شركة الأهلي المالية

طريق الملك سعود، ص.ب. 22216، الرياض 11495، المملكة العربية السعودية
هاتف: +966 920000232

الموقع الإلكتروني: www.alahlicapital.com

2) Names and addresses of Sub-Manager / Investment Adviser

2) اسم وعنوان مدير الصندوق من الباطن و/أو مستشارين الاستثمار (إن وجد)

Acadian Asset Management

260 Franklin Street, Boston, MA 02110.

3) Investment Activities during the period

During the year the fund maintained an underweight stance in the US and Japan, and an overweight stance in Continental Europe.

3) أنشطة الاستثمار خلال الفترة

خلال العام، حافظ الصندوق على مستوى تعريض أقل من المؤشر في الولايات المتحدة واليابان، بينما حافظ على مستوى تعريض أعلى في أوروبا.

4) Report of investment fund's performance during the period

Fund Performance -13.02%
Benchmark Performance -8.99%

4) تقرير الأداء خلال الفترة

أداء الصندوق -13.02%
أداء المؤشر -8.99%

The fund underperformed the benchmark by 403 bps.

انخفض أداء الصندوق عن أداء المؤشر بفارق 403 نقطة أساس.

5) Terms & Conditions Material Changes

1. Amending the fund's Terms & Conditions in order to comply with the requirements of annex (1) of the amended Investment Funds Regulations.
2. Non-fundamental Changes: as shown below:
First: Adding the minimum subscription and the additional subscription through the Individual Saving Program (ISP) - where applicable.
Second: Updating the Fund's Summary.
Third: Amending subparagraphs (k, l, o) in paragraph (3) "Investment Policies and Practices"
Fourth: Amending subparagraphs (a, b) in paragraph (9) "Fees, Charges and Expenses".

5) تغيرات حدثت في شروط وأحكام الصندوق

1. تعديل شروط وأحكام الصندوق للالتزام بمتطلبات الملحق (1) من لائحة صناديق الاستثمار المعدلة.
2. تغييرات غير أساسية: كما هو موضح أدناه:
أولاً: إضافة فقرة الحد الأدنى للاشتراك والاشتراك الإضافي عبر برنامج الادخار (ISP) (حيثما ينطبق).
ثانياً: تحديث ملخص الصندوق.
ثالثاً: تعديل الفقرات الفرعية (ك، ل، س) من الفقرة الرئيسية (3) "سياسات الاستثمار وممارساته".
رابعاً: تحديث الفقرات الفرعية (أ، ب) من الفقرة الرئيسية (9) "مقابل الخدمات والعمولات والأتعاب".
خامساً: تحديث الفقرة الفرعية (ب، هـ) من الفقرة الرئيسية (10) "التقييم والتسعير".

Fifth: Amending subparagraph (b, e) in paragraph (10) "Valuation and Pricing".

Sixth: Amending subparagraph (f) in paragraph (24) "Fund Board".

سادساً: تحديث الفقرة الفرعية (و) من الفقرة الرئيسية (24) "مجلس إدارة الصندوق".

6) Any other information that would enable unitholders to make an informed judgment about the fund's activities during the period

None.

6) أي معلومة أخرى من شأنها أن تُمكن مالكي الوحدات من اتخاذ قرار مدروس ومبني على معلومات كافية بشأن أنشطة الصندوق خلال الفترة

لا يوجد.

7) Investments in other Investment Funds

The fund has not invested substantially in other investment funds.

7) الاستثمار في صناديق استثمارية أخرى

الصندوق لم يستثمر بشكل كبير في صناديق استثمارية أخرى.

8) Special commission received by the fund manager during the period

None.

8) العمولات الخاصة التي حصل عليها مدير الصندوق خلال الفترة

لا يوجد.

9) Any other data and other information required by Investment Fund Regulations to be included in this report

9) أي بيانات ومعلومات أخرى أوجبت لائحة صناديق الاستثمار تضمينها بهذا التقرير

a. Conflict of Interests

There is no conflict of interests.

أ. تعارض في المصالح

لا يوجد تعارض مصالح.

b. Fund Distribution During The Year

No income or dividends will be distributed to Unitholders.

ب. توزيعات الصندوق خلال العام

لا يتم توزيع أي دخل وأرباح على مالكي الوحدات.

c. Incorrect Valuation or Pricing

None.

ج. خطأ في التقويم والتسعير

لا يوجد.

d. Investment Limitation Breaches

None.

د. مخالفة قيود الاستثمار

لا يوجد.

10) Period for the management of the person registered as fund manager

Since August – 2022.

10) مدة إدارة الشخص المسجل كمدير للصندوق

منذ أغسطس – 2022م.

11) A disclosure of the expense ratio of each underlying fund at end of year and the weighted average expense ratio of all underlying funds that invested in (where applicable)

N/A.

11) الإفصاح عن نسبة مصروفات كل صندوق بنهاية العام والمتوسط المرجح لنسبة مصروفات كل الصناديق الرئيسة المستثمر فيها (حيثما ينطبق)

لا ينطبق.

D) Custodian

د) أمين الحفظ

1) Name and address of custodian

The Northern Trust Company of Saudi Arabia
Nakheel Tower, P.O. Box 10175, Riyadh 11433, Saudi Arabia
Tel: +966114188694
Website: www.northerntrust.com

1) اسم أمين الحفظ، وعنوانه

شركة نورذن ترست العربية السعودية
برج النخيل، ص.ب. 10175، الرياض 11433، المملكة العربية السعودية
هاتف: +966114188694
الموقع: www.northerntrust.com

2) Custodian's duties and responsibilities

- Notwithstanding the delegation by a custodian to one or more third parties under the provisions of Investment Funds Regulations or the Capital Market Institutions Regulations, the custodian shall remain fully responsible for compliance with its responsibilities in accordance to the provisions of Investment Funds Regulations.
- The custodian shall be held responsible to the fund manager and unitholders for any losses caused to the investment fund due to the custodian fraud, negligence, misconduct or willful default.
- The custodian shall be responsible for taking custody and protecting the fund's assets on behalf of unitholders, and taking all necessary administrative measures in relation to the custody of the fund's assets.

2) واجبات ومسؤوليات أمين الحفظ

- يعد أمين الحفظ مسؤولاً عن التزاماته وفقاً لأحكام لائحة صناديق الاستثمار، سواء قام بتأدية مسؤولياته بشكل مباشر أم كلف بها طرفاً ثالثاً بموجب أحكام لائحة صناديق الاستثمار أو لائحة مؤسسات السوق المالية.
- يعد أمين الحفظ مسؤولاً تجاه مدير الصندوق ومالكي الوحدات عن خسائر الصندوق الناجمة بسبب احتياله أو إهماله أو سوء تصرفه المتعمد أو تقصيره المتعمد.
- يعد أمين الحفظ مسؤولاً عن حفظ أصول الصندوق وحمايتها لصالح مالكي الوحدات، وهو مسؤول كذلك عن اتخاذ جميع الإجراءات الإدارية اللازمة فيما يتعلق بحفظ أصول الصندوق.

E) Fund Operator

د) مشغل الصندوق

1) Name and address of fund operator

SNB Capital Company
King Saud Road, P.O. Box 22216, Riyadh 11495,
Saudi Arabia
Tel: +966 920000232
Website: www.alahlicapital.com

1) اسم مشغل الصندوق، وعنوانه

شركة الأهلي المالية
طريق الملك سعود، ص.ب. 22216، الرياض 11495،
المملكة العربية السعودية
هاتف: +966 920000232
الموقع الإلكتروني: www.alahlicapital.com

2) Operator's duties and responsibilities

- In relation to investment funds, the fund operator shall be responsible for operating the investment fund.
- The fund operator must maintain the books and records related to the operation of the fund it operates.
- The fund operator must establish a register of unitholders and must maintain it in the Kingdom in accordance to the Investment Funds Regulations.
- The fund operator shall be responsible for the process of dividends distribution (if available) to unitholders.
- The fund operator must process requests for subscriptions or redemption according to the fund's Terms & Conditions.
- The fund operator shall be responsible for calculating the price of the units and valuing the assets of the fund. In so doing, the fund operator shall conduct a full and fair valuation according to the fund's Terms & Conditions.

2) واجبات ومسؤوليات مشغل الصندوق

- يكون مشغل الصندوق مسؤولاً عن تشغيل الصندوق.
- يقوم مشغل الصندوق بالاحتفاظ بالدفاتر والسجلات ذات الصلة بتشغيل الصندوق.
- يقوم مشغل الصندوق بإعداد وتحديث سجل مالكي الوحدات وحفظه في المملكة وفقاً لمتطلبات لائحة صناديق الاستثمار.
- يُعدّ مشغل الصندوق مسؤولاً عن عملية توزيع الأرباح (إن وجدت) حسب سياسة التوزيع المنصوص عليها في شروط وأحكام الصندوق.
- يقوم مشغل الصندوق بإجراءات الاشتراك حسب المنصوص عليها في شروط وأحكام الصندوق.
- يُعدّ مشغل الصندوق مسؤولاً عن تقييم أصول الصندوق تقييماً كاملاً وعادلاً وحساب سعر وحدات الصندوق حسب ما ورد في شروط وأحكام الصندوق.

F) Auditor

و) مراجع الحسابات

Name and Address of Auditor

اسم مراجع الحسابات، عنوانه

KPMG Professional Services

كي بي ام جي للخدمات المهنية

Riyadh Front – Airport Road P.O Box. 92876, Riyadh 11663,
Saudi Arabia

وأجفة الرياض – طريق المطار ص.ب 92876، الرياض 11663 المملكة العربية
السعودية

Tel: +966118748500

هاتف: +966118748500

Website: www.kpmg.com/sa

الموقع الإلكتروني: www.kpmg.com/sa

G) Financial Statements

ز) القوائم المالية

As shown below in the financial statements section.

كما هو موضح أدناه في قسم القوائم المالية.

Annex - Exercised Voting Rights

ملحق - ممارسات التصويت السنوية

Issuer Name	Meeting Date	Country	Proposal Text	Proponent	Mgmt Rec
Surmodics, Inc.	02/10/2022	USA	Elect Director Ronald B. Kalich	Mgmt	For
Surmodics, Inc.	02/10/2022	USA	Elect Director Gary R. Maharaj	Mgmt	For
Surmodics, Inc.	02/10/2022	USA	Fix Number of Directors at Six	Mgmt	For
Surmodics, Inc.	02/10/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
Surmodics, Inc.	02/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Surmodics, Inc.	02/10/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Enanta Pharmaceuticals, Inc.	03/03/2022	USA	Elect Director Mark G. Foletta	Mgmt	For
Enanta Pharmaceuticals, Inc.	03/03/2022	USA	Elect Director Lesley Russell	Mgmt	For
Enanta Pharmaceuticals, Inc.	03/03/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Enanta Pharmaceuticals, Inc.	03/03/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Enanta Pharmaceuticals, Inc.	03/03/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Accept Financial Statements and Statutory Reports	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Approve Discharge of Board and Senior Management	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Approve Allocation of Income and Dividends of CHF 3.10 per Share	Mgmt	For

Novartis AG	03/04/2022	Switzerland	Approve CHF 15.3 Million Reduction in Share Capital via Cancellation of Repurchased Shares	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Authorize Repurchase of up to CHF 10 Billion in Issued Share Capital	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Approve Remuneration of Directors in the Amount of CHF 8.6 Million	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Approve Maximum Remuneration of Executive Committee in the Amount of CHF 91 Million	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Approve Remuneration Report	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Joerg Reinhardt as Director and Board Chairman	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Nancy Andrews as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Ton Buechner as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Patrice Bula as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Elizabeth Doherty as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Bridgette Heller as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Frans van Houten as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Simon Moroney as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Andreas von Planta as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect Charles Sawyers as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reelect William Winters as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Elect Ana de Pro Gonzalo as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Elect Daniel Hochstrasser as Director	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reappoint Patrice Bula as Member of the Compensation Committee	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reappoint Bridgette Heller as Member of the Compensation Committee	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reappoint Simon Moroney as Member of the Compensation Committee	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Reappoint William Winters as Member of the Compensation Committee	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Ratify KPMG AG as Auditors	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Designate Peter Zahn as Independent Proxy	Mgmt	For
Novartis AG	03/04/2022	Switzerland	Transact Other Business (Voting)	Mgmt	For

AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Ornella Barra	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Steven H. Collis	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director D. Mark Durcan	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Richard W. Gochner	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Lon R. Greenberg	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Jane E. Henney	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Kathleen W. Hyle	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Michael J. Long	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Henry W. McGee	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Elect Director Dennis M. Nally	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Approve Omnibus Stock Plan	Mgmt	For
AmerisourceBerg en Corporation	03/10/2022	USA	Adopt a Policy That No Financial Metric Be Adjusted to Exclude Legal or Compliance Costs in Determining Executive Compensation	SH	Against
AmerisourceBerg en Corporation	03/10/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
Demant A/S	03/10/2022	Denmark	Receive Report of Board	Mgmt	
Demant A/S	03/10/2022	Denmark	Accept Financial Statements and Statutory Reports	Mgmt	For
Demant A/S	03/10/2022	Denmark	Approve Allocation of Income and Omission of Dividends	Mgmt	For
Demant A/S	03/10/2022	Denmark	Approve Remuneration Report (Advisory Vote)	Mgmt	For
Demant A/S	03/10/2022	Denmark	Approve Remuneration of Directors in the Amount of DKK 1.2 Million for Chairman, DKK 800,000 for Vice Chairman and DKK 400,000 for Other Directors; Approve Remuneration for Committee Work	Mgmt	For
Demant A/S	03/10/2022	Denmark	Reelect Niels B. Christiansen as Director	Mgmt	For
Demant A/S	03/10/2022	Denmark	Reelect Niels Jacobsen as Director	Mgmt	For
Demant A/S	03/10/2022	Denmark	Reelect Anja Madsen as Director	Mgmt	For
Demant A/S	03/10/2022	Denmark	Reelect Sisse Fjelsted Rasmussen as Director	Mgmt	For

Demant A/S	03/10/2022	Denmark	Reelect Kristian Villumsen as Director	Mgmt	For
Demant A/S	03/10/2022	Denmark	Ratify PricewaterhouseCoopers as Auditors	Mgmt	For
Demant A/S	03/10/2022	Denmark	Approve DKK 1.9 Million Reduction in Share Capital via Share Cancellation for Transfer to Shareholders	Mgmt	For
Demant A/S	03/10/2022	Denmark	Authorize Share Repurchase Program	Mgmt	For
Demant A/S	03/10/2022	Denmark	Approve Guidelines for Incentive-Based Compensation for Executive Management and Board	Mgmt	For
Demant A/S	03/10/2022	Denmark	Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish Authorities	Mgmt	For
Demant A/S	03/10/2022	Denmark	Other Business	Mgmt	
Novo Nordisk A/S	03/24/2022	Denmark	Receive Report of Board	Mgmt	
Novo Nordisk A/S	03/24/2022	Denmark	Accept Financial Statements and Statutory Reports	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve Allocation of Income and Dividends of DKK 6.90 Per Share	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve Remuneration Report (Advisory Vote)	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve Remuneration of Directors for 2021 in the Aggregate Amount of DKK 17.1 Million	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve Remuneration of Directors for 2022 in the Amount of DKK 2.26 Million for the Chairman, DKK 1.51 Million for the Vice Chairman, and DKK 755,000 for Other Directors; Approve Remuneration for Committee Work	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Helge Lund as Director and Board Chair	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Henrik Poulsen as Director and Vice Chair	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Jeppe Christiansen as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Laurence Debroux as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Andreas Fibig as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Sylvie Gregoire as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Kasim Kutay as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Reelect Martin Mackay as Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Elect Choi La Christina Law as New Director	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Ratify Deloitte as Auditors	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve DKK 6 Million Reduction in Share Capital via B Share Cancellation	Mgmt	For

Novo Nordisk A/S	03/24/2022	Denmark	Authorize Share Repurchase Program	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Approve Creation of DKK 45.6 Million Pool of Capital with Preemptive Rights; Approve Creation of DKK 45.6 Million Pool of Capital without Preemptive Rights; Maximum Increase in Share Capital under Both Authorizations up to DKK 45.6 Million	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Amendment to Remuneration Policy for Board of Directors and Executive Management	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Amend Articles Re: Board-Related	Mgmt	For
Novo Nordisk A/S	03/24/2022	Denmark	Other Business	Mgmt	
Genmab A/S	03/29/2022	Denmark	Receive Report of Board	Mgmt	
Genmab A/S	03/29/2022	Denmark	Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Approve Allocation of Income and Omission of Dividends	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Approve Remuneration Report (Advisory Vote)	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Reelect Deirdre P. Connelly as Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Reelect Pernille Erenbjerg as Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Reelect Rolf Hoffmann as Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Reelect Paolo Paoletti as Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Reelect Anders Gersel Pedersen as Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Elect Elizabeth O'Farrell as New Director	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Ratify PricewaterhouseCoopers as Auditors	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Approve Remuneration of Directors in the Amount of DKK 1.2 Million for Chairman, DKK 900,000 for Vice Chairman, and DKK 600,000 for Other Directors	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Authorize Editorial Changes to Adopted Resolutions in Connection with Registration with Danish Authorities	Mgmt	For
Genmab A/S	03/29/2022	Denmark	Other Business	Mgmt	
Sartorius Stedim Biotech SA	03/29/2022	France	Ordinary Business	Mgmt	
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Financial Statements and Discharge Directors	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Consolidated Financial Statements and Statutory Reports	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Allocation of Income and Dividends of EUR 1.26 per Share	Mgmt	For

Sartorius Stedim Biotech SA	03/29/2022	France	Approve Auditors' Special Report on Related-Party Transactions	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Remuneration Policy of Directors; Approve Remuneration of Directors in the Aggregate Amount of EUR 331,800	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Compensation Report of Corporate Officers	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Compensation of Joachim Kreuzburg, Chairman and CEO	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Remuneration Policy of Chairman and CEO	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Remuneration Policy of Vice-CEO	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Reelect Joachim Kreuzburg as Director	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Reelect Pascale Boissel as Director	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Reelect Rene Faber as Director	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Reelect Lothar Kappich as Director	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Reelect Henri Riey as Director	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Filing of Required Documents/Other Formalities	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Extraordinary Business	Mgmt	
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 6 Million	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 6 Million	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Approve Issuance of Equity or Equity-Linked Securities Reserved for Qualified Investors, up to Aggregate Nominal Amount of EUR 6 Million	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 17 to 19	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in Kind	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Capitalization of Reserves of Up to EUR 6 Million for Bonus Issue or Increase in Par Value	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Capital Issuances for Use in Employee Stock Purchase Plans	Mgmt	Against
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans	Mgmt	For
Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Decrease in Share Capital via Cancellation of Repurchased Shares	Mgmt	For

Sartorius Stedim Biotech SA	03/29/2022	France	Authorize Filing of Required Documents/Other Formalities	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Receive Financial Statements and Statutory Reports for Fiscal Year 2020/21 (Non-Voting)	Mgmt	
Carl Zeiss Meditec AG	03/30/2022	Germany	Approve Allocation of Income and Dividends of EUR 0.90 per Share	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Approve Discharge of Management Board for Fiscal Year 2020/21	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Approve Discharge of Supervisory Board for Fiscal Year 2020/21	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Ratify Ernst & Young GmbH as Auditors for Fiscal Year 2021/22	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Approve Creation of EUR 26.5 Million Pool of Authorized Capital with or without Exclusion of Preemptive Rights	Mgmt	For
Carl Zeiss Meditec AG	03/30/2022	Germany	Amend Articles Re: D&O Insurance	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Approve Allocation of Income, with a Final Dividend of JPY 20	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Amend Articles to Disclose Shareholder Meeting Materials on Internet - Indemnify Directors - Indemnify Statutory Auditors	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Elect Director Nakanishi, Eiichi	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Elect Director Nakanishi, Kensuke	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Elect Director Suzuki, Masataka	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Elect Director Nonagase, Yuji	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Elect Director Araki, Yukiko	Mgmt	For
Nakanishi, Inc.	03/30/2022	Japan	Appoint Statutory Auditor Sawada, Yuji	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Accept Financial Statements and Statutory Reports	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Remuneration Report	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Allocation of Income and Dividends of CHF 6.75 per Share	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve 1:10 Stock Split	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Discharge of Board and Senior Management	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Fixed Remuneration of Directors in the Amount of CHF 2.7 Million	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Fixed Remuneration of Executive Committee in the Amount of CHF 9.7 Million	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Approve Long-Term Variable Remuneration of Executive Committee in the Amount of CHF 3.8 Million	Mgmt	For

Straumann Holding AG	04/05/2022	Switzerland	Approve Short-Term Variable Remuneration of Executive Committee in the Amount of CHF 5.6 Million	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Gilbert Achermann as Director and Board Chairman	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Marco Gadola as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Juan Gonzalez as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Beat Luethi as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Petra Rumpf as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Thomas Straumann as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reelect Regula Wallimann as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Elect Nadia Schmidt as Director	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reappoint Beat Luethi as Member of the Nomination and Compensation Committee	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reappoint Regula Wallimann as Member of the Nomination and Compensation Committee	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Reappoint Juan Gonzalez as Member of the Nomination and Compensation Committee	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Appoint Nadia Schmidt as Member of the Nomination and Compensation Committee	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Designate Neovius AG as Independent Proxy	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Ratify Ernst & Young AG as Auditors	Mgmt	For
Straumann Holding AG	04/05/2022	Switzerland	Transact Other Business (Voting)	Mgmt	For
Merck KGaA	04/22/2022	Germany	Receive Financial Statements and Statutory Reports for Fiscal Year 2021 (Non-Voting)	Mgmt	
Merck KGaA	04/22/2022	Germany	Accept Financial Statements and Statutory Reports for Fiscal Year 2021	Mgmt	For
Merck KGaA	04/22/2022	Germany	Approve Allocation of Income and Dividends of EUR 1.85 per Share	Mgmt	For
Merck KGaA	04/22/2022	Germany	Approve Discharge of Management Board for Fiscal Year 2021	Mgmt	For
Merck KGaA	04/22/2022	Germany	Approve Discharge of Supervisory Board for Fiscal Year 2021	Mgmt	For
Merck KGaA	04/22/2022	Germany	Ratify KPMG AG as Auditors for Fiscal Year 2022 and for the Review of Interim Financial Reports for Fiscal Year 2022	Mgmt	For
Merck KGaA	04/22/2022	Germany	Ratify Deloitte GmbH as Auditors for Fiscal Year 2023 and for the Review of Interim Financial Reports for Fiscal Year 2023	Mgmt	For
Merck KGaA	04/22/2022	Germany	Approve Remuneration Report	Mgmt	For

Merck KGaA	04/22/2022	Germany	Approve Creation of EUR 56.5 Million Pool of Authorized Capital with or without Exclusion of Preemptive Rights	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Accept Financial Statements and Statutory Reports	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Approve Final Dividend	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Reappoint PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise the Audit Committee to Fix Remuneration of Auditors	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Said Darwazah as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Siggi Olafsson as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Mazen Darwazah as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Patrick Butler as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Ali Al-Husry as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect John Castellani as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Nina Henderson as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Cynthia Flowers as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Re-elect Douglas Hurt as Director	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Approve Remuneration Report	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Approve the Conversion of the Merger Reserve to a Distributable Reserve	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise Issue of Equity	Mgmt	For

Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise Market Purchase of Ordinary Shares	Mgmt	For
Hikma Pharmaceuticals Plc	04/25/2022	United Kingdom	Authorise the Company to Call General Meeting with Two Weeks' Notice	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director George W. Bickerstaff, III	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director Deborah L. Bix	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director Mark A. DiPaolo	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director Jules Haimovitz	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director Odysseas D. Kostas	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Elect Director Sarah J. Schlesinger	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Innoviva, Inc.	04/25/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
Bio-Rad Laboratories, Inc.	04/26/2022	USA	Elect Director Melinda Litherland	Mgmt	For
Bio-Rad Laboratories, Inc.	04/26/2022	USA	Elect Director Arnold A. Pinkston	Mgmt	For
Bio-Rad Laboratories, Inc.	04/26/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
Getinge AB	04/26/2022	Sweden	Open Meeting	Mgmt	
Getinge AB	04/26/2022	Sweden	Elect Chairman of Meeting	Mgmt	For
Getinge AB	04/26/2022	Sweden	Prepare and Approve List of Shareholders	Mgmt	
Getinge AB	04/26/2022	Sweden	Approve Agenda of Meeting	Mgmt	For
Getinge AB	04/26/2022	Sweden	Designate Inspector(s) of Minutes of Meeting	Mgmt	
Getinge AB	04/26/2022	Sweden	Acknowledge Proper Convening of Meeting	Mgmt	For
Getinge AB	04/26/2022	Sweden	Receive Financial Statements and Statutory Reports	Mgmt	
Getinge AB	04/26/2022	Sweden	Receive Board's and Board Committee's Reports	Mgmt	

Getinge AB	04/26/2022	Sweden	Receive CEO Report	Mgmt	
Getinge AB	04/26/2022	Sweden	Accept Financial Statements and Statutory Reports	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Allocation of Income and Dividends of SEK 4 Per Share	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Carl Bennet	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Johan Bygge	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Cecilia Daun Wennborg	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Barbro Friden	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Dan Frohm	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Sofia Hasselberg	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Johan Malmquist	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Malin Persson	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Kristian Samuelsson	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Johan Stern	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Mattias Perjos	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Rickard Karlsson	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Ake Larsson	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Peter Jormalm	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Discharge of Fredrik Brattborn	Mgmt	For
Getinge AB	04/26/2022	Sweden	Determine Number of Members (9) and Deputy Members (0) of Board	Mgmt	For
Getinge AB	04/26/2022	Sweden	Determine Number of Auditors (1) and Deputy Auditors (0)	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Remuneration of Directors in the Aggregate Amount of SEK 6.1 Million; Approve Remuneration for Committee Work	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Remuneration of Auditors	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Carl Bennet as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Johan Bygge as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Cecilia Daun Wennborg as Director	Mgmt	For

Getinge AB	04/26/2022	Sweden	Reelect Barbro Friden as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Dan Frohm as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Johan Malmquist as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Mattias Perjos as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Malin Persson as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Kristian Samuelsson as Director	Mgmt	For
Getinge AB	04/26/2022	Sweden	Reelect Johan Malmquist as Board Chair	Mgmt	For
Getinge AB	04/26/2022	Sweden	Ratify PricewaterhouseCoopers as Auditors	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Remuneration Report	Mgmt	For
Getinge AB	04/26/2022	Sweden	Approve Remuneration Policy And Other Terms of Employment For Executive Management	Mgmt	For
Getinge AB	04/26/2022	Sweden	Close Meeting	Mgmt	
Medistim ASA	04/27/2022	Norway	Approve Notice of Meeting and Agenda; Registration of Attending Shareholders and Proxies	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Chairman of Meeting; Designate Inspector(s) of Minutes of Meeting	Mgmt	For
Medistim ASA	04/27/2022	Norway	Accept Annual Report	Mgmt	For
Medistim ASA	04/27/2022	Norway	Accept Financial Statements and Statutory Reports	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Allocation of Income; Authorize Board to Distribute Dividends of NOK 3.75 Per Share	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Remuneration Statement	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Remuneration of Auditors	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Torben Jorgensen as Director	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Lars Ronn as Director	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Tove Raanes as Director	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Anthea Arff-Pettersen as Director	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Remuneration of Directors in the Amount of NOK 450,000 for Chairman and NOK 250,000 for Other Directors	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Vegard Soraunet as Member of Nominating Committee	Mgmt	For
Medistim ASA	04/27/2022	Norway	Elect Jonathan Schonback as Member of Nominating Committee	Mgmt	For

Medistim ASA	04/27/2022	Norway	Approve Remuneration of Nominating Committee	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Remuneration of Remuneration Committee	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Remuneration of Audit Committee	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Financial Assistance to Senior Executives in Connection with Purchase of Shares Under a Long-Term Incentive Agreement	Mgmt	For
Medistim ASA	04/27/2022	Norway	Approve Creation of NOK 458,433 Pool of Capital without Preemptive Rights	Mgmt	For
Medistim ASA	04/27/2022	Norway	Authorize Share Repurchase Program	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Craig H. Barratt	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Joseph C. Beery	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Gary S. Guthart	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Amal M. Johnson	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Don R. Kania	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Amy L. Ladd	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Keith R. Leonard, Jr.	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Alan J. Levy	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Jami Dover Nachtsheim	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Monica P. Reed	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Elect Director Mark J. Rubash	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Intuitive Surgical, Inc.	04/28/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Darius Adamczyk	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Mary C. Beckerle	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director D. Scott Davis	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Ian E. L. Davis	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Jennifer A. Doudna	Mgmt	For

Johnson & Johnson	04/28/2022	USA	Elect Director Joaquin Duato	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Alex Gorsky	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Marillyn A. Hewson	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Hubert Joly	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Mark B. McClellan	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Anne M. Mulcahy	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director A. Eugene Washington	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Mark A. Weinberger	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Elect Director Nadja Y. West	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Approve Omnibus Stock Plan	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Johnson & Johnson	04/28/2022	USA	Adopt a Mandatory Arbitration Bylaw *Withdrawn Resolution*	SH	
Johnson & Johnson	04/28/2022	USA	Report on a Civil Rights, Equity, Diversity and Inclusion Audit	SH	Against
Johnson & Johnson	04/28/2022	USA	Oversee and Report a Racial Equity Audit	SH	Against
Johnson & Johnson	04/28/2022	USA	Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics	SH	Against
Johnson & Johnson	04/28/2022	USA	Report on Public Health Costs of Limited Sharing of Vaccine Technology	SH	Against
Johnson & Johnson	04/28/2022	USA	Discontinue Global Sales of Baby Powder Containing Talc	SH	Against
Johnson & Johnson	04/28/2022	USA	Report on Charitable Contributions	SH	Against
Johnson & Johnson	04/28/2022	USA	Publish Third-Party Review of Alignment of Company's Lobbying Activities with its Public Statements	SH	Against
Johnson & Johnson	04/28/2022	USA	Adopt Policy to Include Legal and Compliance Costs in Incentive Compensation Metrics	SH	Against
Johnson & Johnson	04/28/2022	USA	Consider Pay Disparity Between Executives and Other Employees	SH	Against
Pfizer Inc.	04/28/2022	USA	Elect Director Ronald E. Blaylock	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Albert Bourla	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Susan Desmond-Hellmann	Mgmt	For

Pfizer Inc.	04/28/2022	USA	Elect Director Joseph J. Echevarria	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Scott Gottlieb	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Helen H. Hobbs	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Susan Hockfield	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Dan R. Littman	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Shantanu Narayen	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director Suzanne Nora Johnson	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director James Quincey	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Elect Director James C. Smith	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Pfizer Inc.	04/28/2022	USA	Amend Proxy Access Right	SH	Against
Pfizer Inc.	04/28/2022	USA	Report on Congruency of Political Electioneering Expenditures with Company Values and Policies	SH	Against
Pfizer Inc.	04/28/2022	USA	Report on Feasibility of Technology Transfer to Boost Covid-19 Vaccine Production	SH	Against
Pfizer Inc.	04/28/2022	USA	Report on Board Oversight of Risks Related to Anticompetitive Practices	SH	Against
Pfizer Inc.	04/28/2022	USA	Report on Public Health Costs of Limited Sharing of Vaccine Technology	SH	Against
Singapore Medical Group Limited	04/28/2022	Singapore	Adopt Financial Statements and Directors' and Auditors' Reports	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Approve Final and Special Dividend	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Elect Tony Tan Choon Keat as Director	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Elect Beng Teck Liang as Director	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Approve Directors' Fees	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Approve Ernst & Young LLP as Auditors and Authorize Board to Fix Their Remuneration	Mgmt	For

Singapore Medical Group Limited	04/28/2022	Singapore	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Approve Grant of Options and Issuance of Shares Under the SMG Share Option Scheme	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Approve Grant of Awards and Issuance of Shares Under the SMG Share Plan	Mgmt	For
Singapore Medical Group Limited	04/28/2022	Singapore	Authorize Share Repurchase Program	Mgmt	For
UCB SA	04/28/2022	Belgium	Annual/Special Meeting Agenda	Mgmt	
UCB SA	04/28/2022	Belgium	Ordinary Part	Mgmt	
UCB SA	04/28/2022	Belgium	Receive Directors' Reports (Non-Voting)	Mgmt	
UCB SA	04/28/2022	Belgium	Receive Auditors' Reports (Non-Voting)	Mgmt	
UCB SA	04/28/2022	Belgium	Receive Consolidated Financial Statements and Statutory Reports (Non-Voting)	Mgmt	
UCB SA	04/28/2022	Belgium	Approve Financial Statements, Allocation of Income, and Dividends of EUR 1.30 per Share	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Remuneration Report	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Remuneration of Directors	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Discharge of Directors	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Discharge of Auditors	Mgmt	For
UCB SA	04/28/2022	Belgium	Reelect Kay Davies as Director	Mgmt	For
UCB SA	04/28/2022	Belgium	Indicate Kay Davies as Independent Director	Mgmt	For
UCB SA	04/28/2022	Belgium	Reelect Jean-Christophe Tellier as Director	Mgmt	For
UCB SA	04/28/2022	Belgium	Reelect Cedric van Rijckevorsel as Director	Mgmt	For
UCB SA	04/28/2022	Belgium	Special Part	Mgmt	
UCB SA	04/28/2022	Belgium	Approve Long-Term Incentive Plans	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Change-of-Control Clause Re: EMTN Program Renewal	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Change-of-Control Clause Re: European Investment Bank Facility Agreement	Mgmt	For
UCB SA	04/28/2022	Belgium	Approve Change-of-Control Clause Re: Term Facility Agreement	Mgmt	For

UCB SA	04/28/2022	Belgium	Extraordinary Part of the Extraordinary General Meeting	Mgmt	
UCB SA	04/28/2022	Belgium	Receive Special Board Report Re: Authorized Capital	Mgmt	
UCB SA	04/28/2022	Belgium	Renew Authorization to Increase Share Capital within the Framework of Authorized Capital	Mgmt	For
UCB SA	04/28/2022	Belgium	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	Mgmt	For
UCB SA	04/28/2022	Belgium	Amend Article 19 Re: Proceeding of the Board Being Set Down in Minutes	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Robert J. Alpern	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Sally E. Blount	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Robert B. Ford	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Paola Gonzalez	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Michelle A. Kumbier	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Darren W. McDew	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Nancy McKinstry	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director William A. Osborn	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Michael F. Roman	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Daniel J. Starks	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director John G. Stratton	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Elect Director Glenn F. Tilton	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Abbott Laboratories	04/29/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
Abbott Laboratories	04/29/2022	USA	Require Independent Board Chair	SH	Against
Abbott Laboratories	04/29/2022	USA	Adopt Policy on 10b5-1 Plans	SH	Against
Abbott Laboratories	04/29/2022	USA	Report on Lobbying Payments and Policy	SH	Against
Abbott Laboratories	04/29/2022	USA	Report on Public Health Costs of Antimicrobial Resistance	SH	Against
AstraZeneca Plc	04/29/2022	United Kingdom	Accept Financial Statements and Statutory Reports	Mgmt	For

AstraZeneca Plc	04/29/2022	United Kingdom	Approve Dividends	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Reappoint PricewaterhouseCoopers LLP as Auditors	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise Board to Fix Remuneration of Auditors	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Leif Johansson as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Pascal Soriot as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Elect Aradhana Sarin as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Philip Broadley as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Euan Ashley as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Michel Demare as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Deborah DiSanzo as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Diana Layfield as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Sheri McCoy as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Tony Mok as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Nazneen Rahman as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Elect Andreas Rummelt as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Re-elect Marcus Wallenberg as Director	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Approve Remuneration Report	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise UK Political Donations and Expenditure	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise Issue of Equity	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise Market Purchase of Ordinary Shares	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Authorise the Company to Call General Meeting with Two Weeks' Notice	Mgmt	For
AstraZeneca Plc	04/29/2022	United Kingdom	Approve Savings Related Share Option Scheme	Mgmt	For

Bayer AG	04/29/2022	Germany	Receive Financial Statements and Statutory Reports; Approve Allocation of Income and Dividends of EUR 2.00 per Share for Fiscal Year 2021	Mgmt	For
Bayer AG	04/29/2022	Germany	Approve Discharge of Management Board for Fiscal Year 2021	Mgmt	For
Bayer AG	04/29/2022	Germany	Approve Discharge of Supervisory Board for Fiscal Year 2021	Mgmt	For
Bayer AG	04/29/2022	Germany	Reelect Paul Achleitner to the Supervisory Board	Mgmt	For
Bayer AG	04/29/2022	Germany	Reelect Norbert Bischofberger to the Supervisory Board	Mgmt	For
Bayer AG	04/29/2022	Germany	Reelect Colleen Goggins to the Supervisory Board	Mgmt	For
Bayer AG	04/29/2022	Germany	Approve Remuneration Report	Mgmt	For
Bayer AG	04/29/2022	Germany	Approve Affiliation Agreement with Bayer Chemicals GmbH	Mgmt	For
Bayer AG	04/29/2022	Germany	Ratify Deloitte GmbH as Auditors for Fiscal Year 2022	Mgmt	For
El.En. SpA	04/29/2022	Italy	Ordinary Business	Mgmt	
El.En. SpA	04/29/2022	Italy	Approve Financial Statements, Statutory Reports, and Allocation of Income	Mgmt	For
El.En. SpA	04/29/2022	Italy	Approve Remuneration Policy	Mgmt	For
El.En. SpA	04/29/2022	Italy	Approve Second Section of the Remuneration Report	Mgmt	For
El.En. SpA	04/29/2022	Italy	Appoint Internal Statutory Auditors (Slate Election) - Choose One of the Following Slates	Mgmt	
El.En. SpA	04/29/2022	Italy	Slate 1 Submitted by Andrea Cangioli	SH	None
El.En. SpA	04/29/2022	Italy	Slate 2 Submitted by Institutional Investors (Assogestioni)	SH	None
El.En. SpA	04/29/2022	Italy	Appoint Chairman of Internal Statutory Auditors	SH	None
El.En. SpA	04/29/2022	Italy	Approve Internal Auditors' Remuneration	Mgmt	For
El.En. SpA	04/29/2022	Italy	Extraordinary Business	Mgmt	
El.En. SpA	04/29/2022	Italy	Amend Articles Re: Article 19	Mgmt	For
El.En. SpA	04/29/2022	Italy	Amend Articles Re: Article 20	Mgmt	For
El.En. SpA	04/29/2022	Italy	Amend Articles Re: Article 25	Mgmt	For
Recordati SpA	04/29/2022	Italy	Ordinary Business	Mgmt	
Recordati SpA	04/29/2022	Italy	Management Proposals	Mgmt	
Recordati SpA	04/29/2022	Italy	Accept Financial Statements and Statutory Reports	Mgmt	For

Recordati SpA	04/29/2022	Italy	Approve Allocation of Income	Mgmt	For
Recordati SpA	04/29/2022	Italy	Shareholder Proposals Submitted by Rossini Sarl	Mgmt	
Recordati SpA	04/29/2022	Italy	Fix Number of Directors	SH	None
Recordati SpA	04/29/2022	Italy	Fix Board Terms for Directors	SH	None
Recordati SpA	04/29/2022	Italy	Appoint Directors (Slate Election)	Mgmt	
Recordati SpA	04/29/2022	Italy	Slate Submitted by Rossini Sarl	SH	None
Recordati SpA	04/29/2022	Italy	Management Proposals	Mgmt	
Recordati SpA	04/29/2022	Italy	Approve Remuneration of Directors	Mgmt	For
Recordati SpA	04/29/2022	Italy	Deliberations Pursuant to Article 2390 of Civil Code Re: Decisions Inherent to Authorization of Board Members to Assume Positions in Competing Companies	Mgmt	For
Recordati SpA	04/29/2022	Italy	Approve Remuneration Policy	Mgmt	For
Recordati SpA	04/29/2022	Italy	Approve Second Section of the Remuneration Report	Mgmt	For
Recordati SpA	04/29/2022	Italy	Authorize Share Repurchase Program and Reissuance of Repurchased Shares	Mgmt	For
Recordati SpA	04/29/2022	Italy	Deliberations on Possible Legal Action Against Directors if Presented by Shareholders	Mgmt	None
Eli Lilly and Company	05/02/2022	USA	Elect Director Ralph Alvarez	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Elect Director Kimberly H. Johnson	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Elect Director Juan R. Luciano	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Declassify the Board of Directors	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Eliminate Supermajority Voting Provisions	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Amend Articles of Incorporation to Allow Shareholders to Amend Bylaws	Mgmt	For
Eli Lilly and Company	05/02/2022	USA	Require Independent Board Chair	SH	Against
Eli Lilly and Company	05/02/2022	USA	Report on Lobbying Payments and Policy	SH	Against
Eli Lilly and Company	05/02/2022	USA	Publish Third-Party Review of Alignment of Company's Lobbying Activities with its Public Statements	SH	Against

Eli Lilly and Company	05/02/2022	USA	Report on Board Oversight of Risks Related to Anticompetitive Pricing Strategies	SH	Against
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Kieran T. Gallahue	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Leslie S. Heisz	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Paul A. LaViolette	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Steven R. Loranger	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Martha H. Marsh	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Michael A. Mussallem	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Ramona Sequeira	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Elect Director Nicholas J. Valeriani	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Edwards Lifesciences Corporation	05/03/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
Sanofi	05/03/2022	France	Ordinary Business	Mgmt	
Sanofi	05/03/2022	France	Approve Financial Statements and Statutory Reports	Mgmt	For
Sanofi	05/03/2022	France	Approve Consolidated Financial Statements and Statutory Reports	Mgmt	For
Sanofi	05/03/2022	France	Approve Allocation of Income and Dividends of EUR 3.33 per Share	Mgmt	For
Sanofi	05/03/2022	France	Reelect Paul Hudson as Director	Mgmt	For
Sanofi	05/03/2022	France	Reelect Christophe Babule as Director	Mgmt	For
Sanofi	05/03/2022	France	Reelect Patrick Kron as Director	Mgmt	For
Sanofi	05/03/2022	France	Reelect Gilles Schnepf as Director	Mgmt	For

Sanofi	05/03/2022	France	Elect Carole Ferrand as Director	Mgmt	For
Sanofi	05/03/2022	France	Elect Emile Voest as Director	Mgmt	For
Sanofi	05/03/2022	France	Elect Antoine Yver as Director	Mgmt	For
Sanofi	05/03/2022	France	Approve Compensation Report of Corporate Officers	Mgmt	For
Sanofi	05/03/2022	France	Approve Compensation of Serge Weinberg, Chairman of the Board	Mgmt	For
Sanofi	05/03/2022	France	Approve Compensation of Paul Hudson, CEO	Mgmt	For
Sanofi	05/03/2022	France	Approve Remuneration Policy of Directors	Mgmt	For
Sanofi	05/03/2022	France	Approve Remuneration Policy of Chairman of the Board	Mgmt	For
Sanofi	05/03/2022	France	Approve Remuneration Policy of CEO	Mgmt	For
Sanofi	05/03/2022	France	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	Mgmt	For
Sanofi	05/03/2022	France	Extraordinary Business	Mgmt	
Sanofi	05/03/2022	France	Amend Article 25 of Bylaws Re: Dividends	Mgmt	For
Sanofi	05/03/2022	France	Authorize Filing of Required Documents/Other Formalities	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Accept Financial Statements and Statutory Reports	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Approve Remuneration Report	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Approve Remuneration Policy	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Elect Anne Beal as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Elect Harry Dietz as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Sir Jonathan Symonds as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Dame Emma Walmsley as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Charles Bancroft as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Vindi Banga as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Hal Barron as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Dame Vivienne Cox as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Lynn Elsenhans as Director	Mgmt	For

GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Laurie Glimcher as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Jesse Goodman as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Iain Mackay as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Re-elect Urs Rohner as Director	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Reappoint Deloitte LLP as Auditors	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise the Audit & Risk Committee to Fix Remuneration of Auditors	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise UK Political Donations and Expenditure	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise Issue of Equity	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise Market Purchase of Ordinary Shares	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Approve the Exemption from Statement of the Name of the Senior Statutory Auditor in Published Copies of the Auditors' Reports	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Authorise the Company to Call General Meeting with Two Weeks' Notice	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Approve Share Save Plan	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Approve Share Reward Plan	Mgmt	For
GlaxoSmithKline Plc	05/04/2022	United Kingdom	Adopt New Articles of Association	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Mary K. Brainerd	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Giovanni Caforio	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Srikant M. Datar	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Allan C. Golston	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Kevin A. Lobo	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Sherilyn S. McCoy	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Andrew K. Silvernail	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Lisa M. Skeete Tatum	Mgmt	For

Stryker Corporation	05/04/2022	USA	Elect Director Ronda E. Stryker	Mgmt	For
Stryker Corporation	05/04/2022	USA	Elect Director Rajeev Suri	Mgmt	For
Stryker Corporation	05/04/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Stryker Corporation	05/04/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Stryker Corporation	05/04/2022	USA	Amend Proxy Access Right	SH	Against
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Robert F. Spoerry	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Wah-Hui Chu	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Domitille Doat-Le Bigot	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Olivier A. Filliol	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Elisha W. Finney	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Richard Francis	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Michael A. Kelly	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Elect Director Thomas P. Salice	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Mettler-Toledo International Inc.	05/05/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Jorge A. Caballero	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Mark G. Foletta	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Teri G. Fontenot	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director R. Jeffrey Harris	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Daphne E. Jones	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Martha H. Marsh	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Susan R. Salka	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Sylvia Trent-Adams	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Elect Director Douglas D. Wheat	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For

AMN Healthcare Services, Inc.	05/06/2022	USA	Approve Qualified Employee Stock Purchase Plan	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
AMN Healthcare Services, Inc.	05/06/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
Danaher Corporation	05/10/2022	USA	Elect Director Rainer M. Blair	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Linda Filler	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Teri List	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Walter G. Lohr, Jr.	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Jessica L. Mega	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Mitchell P. Rales	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Steven M. Rales	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Pardis C. Sabeti	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director A. Shane Sanders	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director John T. Schwieters	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Alan G. Spoon	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Raymond C. Stevens	Mgmt	For
Danaher Corporation	05/10/2022	USA	Elect Director Elias A. Zerhouni	Mgmt	For
Danaher Corporation	05/10/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Danaher Corporation	05/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Danaher Corporation	05/10/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Open Meeting	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Elect Chairman of Meeting	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Prepare and Approve List of Shareholders	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Agenda of Meeting	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Designate Inspector(s) of Minutes of Meeting	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Acknowledge Proper Convening of Meeting	Mgmt	For

Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Receive Financial Statements and Statutory Reports	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Receive President's Report	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Receive Report on Work of Board and Committees	Mgmt	
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Accept Financial Statements and Statutory Reports	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Allocation of Income and Omission of Dividends	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Hakan Bjorklund	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Annette Clancy	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Matthew Gantz	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Lennart Johansson	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Helena Saxon	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Staffan Schuberg	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Elisabeth Svanberg	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Filippa Stenberg	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Anders Ullman	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Pia Axelson	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Erika Husing	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Linda Larsson	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of Katy Mazibuko	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Discharge of CEO Guido Oelkers	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Remuneration of Directors in the Amount of SEK 900,000 for Chairman, and SEK 550,000 for Other Directors; Approve Remuneration for Committee Work; Approve Meeting Fees	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Remuneration of Auditors	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Determine Number of Members (7) and Deputy Members (0) of Board	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Determine Number of Auditors (1) and Deputy Auditors (0)	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Hakan Bjorklund as Director	Mgmt	For

Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Annette Clancy as Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Matthew Gantz as Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Helena Saxon as Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Staffan Schuberg as Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Filippa Stenberg as Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Elect Bo Jesper Hansen as New Director	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Reelect Hakan Bjorklund as Board Chair	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Ratify Ernst & Young as Auditors	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Remuneration Report	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Long Term Incentive Program (Management Program)	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Long Term Incentive Program (All Employee Program)	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Equity Plan Financing	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Alternative Equity Plan Financing	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Creation of Pool of Capital without Preemptive Rights	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Approve Transfer of Shares in Connection with Previous Share Programs	Mgmt	For
Swedish Orphan Biovitrum AB	05/10/2022	Sweden	Close Meeting	Mgmt	
IDEXX Laboratories, Inc.	05/11/2022	USA	Elect Director Jonathan W. Ayers	Mgmt	For
IDEXX Laboratories, Inc.	05/11/2022	USA	Elect Director Stuart M. Essig	Mgmt	For
IDEXX Laboratories, Inc.	05/11/2022	USA	Elect Director Jonathan J. Mazelsky	Mgmt	For
IDEXX Laboratories, Inc.	05/11/2022	USA	Elect Director M. Anne Szostak	Mgmt	For
IDEXX Laboratories, Inc.	05/11/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
IDEXX Laboratories, Inc.	05/11/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Alkermes Plc	05/13/2022	Ireland	Adopt Plurality Voting for Contested Election of Directors	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Wanda M. Austin	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Robert A. Bradway	Mgmt	For

Amgen Inc.	05/17/2022	USA	Elect Director Brian J. Druker	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Robert A. Eckert	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Greg C. Garland	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Charles M. Holley, Jr.	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director S. Omar Ishrak	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Tyler Jacks	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Ellen J. Kullman	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Amy E. Miles	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director Ronald D. Sugar	Mgmt	For
Amgen Inc.	05/17/2022	USA	Elect Director R. Sanders Williams	Mgmt	For
Amgen Inc.	05/17/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Amgen Inc.	05/17/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Kevin C. Clark	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director W. Larry Cash	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Thomas C. Dircks	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Gale Fitzgerald	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Darrell S. Freeman, Sr.	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director John A. Martins	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Janice E. Nevin	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Elect Director Mark Perlberg	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
Cross Country Healthcare, Inc.	05/17/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director Vivek Jain	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director George A. Lopez	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director David C. Greenberg	Mgmt	For

ICU Medical, Inc.	05/17/2022	USA	Elect Director Elisha W. Finney	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director David F. Hoffmeister	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director Donald M. Abbey	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director Laurie Hernandez	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director Kolleen T. Kennedy	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Elect Director William Seeger	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
ICU Medical, Inc.	05/17/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Mohamad Ali	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Stanley M. Bergman	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director James P. Breslawski	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Deborah Derby	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Joseph L. Herring	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Kurt P. Kuehn	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Philip A. Laskawy	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Anne H. Margulies	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Mark E. Mlotek	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Steven Paladino	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Carol Raphael	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director E. Dianne Rekow	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Scott Serota	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Bradley T. Sheares	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Elect Director Reed V. Tuckson	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Henry Schein, Inc.	05/18/2022	USA	Ratify BDO USA, LLP as Auditors	Mgmt	For

Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Marc N. Casper	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Nelson J. Chai	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Ruby R. Chandy	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director C. Martin Harris	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Tyler Jacks	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director R. Alexandra Keith	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Jim P. Manzi	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director James C. Mullen	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Lars R. Sorensen	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Debora L. Spar	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Scott M. Sperling	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Elect Director Dion J. Weisler	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Thermo Fisher Scientific Inc.	05/18/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Sangeeta Bhatia	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Lloyd Carney	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Alan Garber	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Terrence Kearney	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Reshma Kewalramani	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Yuchun Lee	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Jeffrey Leiden	Mgmt	For

Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Margaret McGlynn	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Diana McKenzie	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Bruce Sachs	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Elect Director Suketu "Suky" Upadhyay	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Vertex Pharmaceuticals Incorporated	05/18/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Elect Director F. Ann Millner	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Elect Director Thomas J. Gunderson	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Elect Director Laura S. Kaiser	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Elect Director Michael R. McDonnell	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Merit Medical Systems, Inc.	05/19/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
Institutional Account Detail (IA Name, IA Number)	Ballot Status	Instructor Name	Votable Shares	Shares Voted	
Zoetis Inc.	05/19/2022	USA	Elect Director Paul M. Bisaro	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Elect Director Frank A. D'Amelio	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Elect Director Michael B. McCallister	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For

Zoetis Inc.	05/19/2022	USA	Eliminate Supermajority Vote Requirements	Mgmt	For
Zoetis Inc.	05/19/2022	USA	Declassify the Board of Directors	Mgmt	For
Hikma Pharmaceuticals Plc	05/20/2022	United Kingdom	Approve the Conversion of the Merger Reserve to a Distributable Reserve	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Douglas M. Baker, Jr.	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Mary Ellen Coe	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Pamela J. Craig	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Robert M. Davis	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Kenneth C. Frazier	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Thomas H. Glocer	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Risa J. Lavizzo-Mourey	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Stephen L. Mayo	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Paul B. Rothman	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Patricia F. Russo	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Christine E. Seidman	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Inge G. Thulin	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Kathy J. Warden	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Elect Director Peter C. Wendell	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Merck & Co., Inc.	05/24/2022	USA	Require Independent Board Chair	SH	Against
Merck & Co., Inc.	05/24/2022	USA	Report on Access to COVID-19 Products	SH	Against
Merck & Co., Inc.	05/24/2022	USA	Report on Lobbying Payments and Policy	SH	Against
HealthStream, Inc.	05/26/2022	USA	Elect Director Thompson S. Dent	Mgmt	For
HealthStream, Inc.	05/26/2022	USA	Elect Director William W. Stead	Mgmt	For
HealthStream, Inc.	05/26/2022	USA	Elect Director Deborah Taylor Tate	Mgmt	For

HealthStream, Inc.	05/26/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
HealthStream, Inc.	05/26/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
HealthStream, Inc.	05/26/2022	USA	Approve Omnibus Stock Plan	Mgmt	For
Masimo Corporation	05/26/2022	USA	Elect Director Adam Mikkelsen	Mgmt	For
Masimo Corporation	05/26/2022	USA	Elect Director Craig Reynolds	Mgmt	For
Masimo Corporation	05/26/2022	USA	Ratify Grant Thornton LLP as Auditors	Mgmt	For
Masimo Corporation	05/26/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Bruker Corporation	06/01/2022	USA	Elect Director Bonnie H. Anderson	Mgmt	For
Bruker Corporation	06/01/2022	USA	Elect Director Frank H. Laukien	Mgmt	For
Bruker Corporation	06/01/2022	USA	Elect Director John Ornell	Mgmt	For
Bruker Corporation	06/01/2022	USA	Elect Director Richard A. Packer	Mgmt	For
Bruker Corporation	06/01/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Bruker Corporation	06/01/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Bruker Corporation	06/01/2022	USA	Approve Qualified Employee Stock Purchase Plan	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Receive Financial Statements and Statutory Reports for Fiscal Year 2021 (Non-Voting)	Mgmt	
Dermapharm Holding SE	06/01/2022	Germany	Approve Allocation of Income and Dividends of EUR 2.17 per Share	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Approve Discharge of Management Board for Fiscal Year 2021	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Approve Discharge of Supervisory Board for Fiscal Year 2021	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Ratify Grant Thornton AG as Auditors for Fiscal Year 2022, for the Review of Interim Financial Statements for Fiscal Year 2022 and for the Review of Interim Financial Statements Until 2023 AGM	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Approve Remuneration Report	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Reelect Wilhelm Beier to the Supervisory Board	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Reelect Erwin Kern to the Supervisory Board	Mgmt	For
Dermapharm Holding SE	06/01/2022	Germany	Reelect Lothar Lanz to the Supervisory Board	Mgmt	For
Sensus Healthcare, Inc.	06/03/2022	USA	Elect Director John Heinrich	Mgmt	For

Sensus Healthcare, Inc.	06/03/2022	USA	Elect Director Anthony Petrelli	Mgmt	For
Sensus Healthcare, Inc.	06/03/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Sensus Healthcare, Inc.	06/03/2022	USA	Advisory Vote on Say on Pay Frequency	Mgmt	Three Years
Sensus Healthcare, Inc.	06/03/2022	USA	Ratify Marcum LLP as Auditors	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Tim Cabral	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Mark Carges	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Paul E. Chamberlain	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Peter P. Gassner	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Mary Lynne Hedley	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Priscilla Hung	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Tina Hunt	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Marshall Mohr	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Gordon Ritter	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Paul Sekhri	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Elect Director Matthew J. Wallach	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Amend Omnibus Stock Plan	Mgmt	For
Veeva Systems Inc.	06/09/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
Amphastar Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Jack Yongfeng Zhang	Mgmt	For
Amphastar Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Richard Prins	Mgmt	For
Amphastar Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Diane G. Gerst	Mgmt	For
Amphastar Pharmaceuticals, Inc.	06/10/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Amphastar Pharmaceuticals, Inc.	06/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For

Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Bonnie L. Bassler	Mgmt	For
Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Michael S. Brown	Mgmt	For
Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director Leonard S. Schleifer	Mgmt	For
Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Elect Director George D. Yancopoulos	Mgmt	For
Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
Regeneron Pharmaceuticals, Inc.	06/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Consolidated and Standalone Financial Statements	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Non-Financial Information Statement	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Allocation of Income and Dividends	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Discharge of Board	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Ratify Appointment of and Elect Marina Del Corral Tellez as Director	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Annual Maximum Remuneration	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Amend Remuneration Policy	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Approve Reduction in Share Capital via Amortization of Treasury Shares	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Renew Appointment of KPMG Auditores as Auditor	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Authorize Board to Ratify and Execute Approved Resolutions	Mgmt	For
Laboratorios Farmaceuticos Rovi SA	06/14/2022	Spain	Advisory Vote on Remuneration Report	Mgmt	For

Incyte Corporation	06/15/2022	USA	Elect Director Julian C. Baker	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Jean-Jacques Bienaime	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Otis W. Brawley	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Paul J. Clancy	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Jacquelyn A. Fouse	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Edmund P. Harrigan	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Katherine A. High	Mgmt	For
Incyte Corporation	06/15/2022	USA	Elect Director Herve Hoppenot	Mgmt	For
Incyte Corporation	06/15/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Incyte Corporation	06/15/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Ilan Daskal	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Eric J. Guerin	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Lisa Wipperman Heine	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Joshua H. Levine	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Bryant M. Moore	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Alice D. Schroeder	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Elect Director Thomas J. Sullivan	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Amend Qualified Employee Stock Purchase Plan	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Natus Medical Incorporated	06/15/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Accept Financial Statements and Statutory Reports	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Remuneration Report (Non-Binding)	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Allocation of Income and Dividends of CHF 4.40 per Share	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Discharge of Board and Senior Management	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Increase in Minimum Size of Board to Five Members and Maximum Size to Ten Members	Mgmt	For

Sonova Holding AG	06/15/2022	Switzerland	Reelect Robert Spoerry as Director and Board Chair	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Stacy Seng as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Lynn Bleil as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Gregory Behar as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Lukas Braunschweiler as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Roland Diggelmann as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Ronald van der Vis as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Jinlong Wang as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reelect Adrian Widmer as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Elect Julie Tay as Director	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reappoint Stacy Seng as Member of the Nomination and Compensation Committee	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reappoint Lukas Braunschweiler as Member of the Nomination and Compensation Committee	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Reappoint Roland Diggelmann as Member of the Nomination and Compensation Committee	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Ratify Ernst & Young AG as Auditors	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Designate Keller KLG as Independent Proxy	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Remuneration of Directors in the Amount of CHF 3.5 Million	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Remuneration of Executive Committee in the Amount of CHF 16 Million	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve CHF 100,621.90 Reduction in Share Capital as Part of the Share Buyback Program via Cancellation of Repurchased Shares	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Approve Extension of Existing Authorized Capital Pool of CHF 305,798.59 with or without Exclusion of Preemptive Rights	Mgmt	For
Sonova Holding AG	06/15/2022	Switzerland	Transact Other Business (Voting)	Mgmt	For
Atea Pharmaceuticals, Inc.	06/17/2022	USA	Elect Director Bruno Lucidi	Mgmt	For
Atea Pharmaceuticals, Inc.	06/17/2022	USA	Elect Director Polly A. Murphy	Mgmt	For
Atea Pharmaceuticals, Inc.	06/17/2022	USA	Elect Director Bruce Polsky	Mgmt	For

Atea Pharmaceuticals, Inc.	06/17/2022	USA	Advisory Vote on Say on Pay Frequency	Mgmt	One Year
Atea Pharmaceuticals, Inc.	06/17/2022	USA	Ratify KPMG LLP as Auditors	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Annual Meeting Agenda	Mgmt	
QIAGEN NV	06/23/2022	Netherlands	Adopt Financial Statements and Statutory Reports	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Approve Remuneration Report	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Approve Discharge of Management Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Approve Discharge of Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Metin Colpan to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Thomas Ebeling to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Toralf Haag to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Ross L. Levine to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Elaine Mardis to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Eva Pisa to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Lawrence A. Rosen to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Elect Elizabeth E. Tallett to Supervisory Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Reelect Thierry Bernard to Management Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Reelect Roland Sackers to Management Board	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Ratify KPMG Accountants N.V. as Auditors	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Grant Supervisory Board Authority to Issue Shares	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Authorize Supervisory Board to Exclude Preemptive Rights from Share Issuances	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Authorize Repurchase of Shares	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Approve Discretionary Rights for the Managing Board to Implement Capital Repayment by Means of Synthetic Share Repurchase	Mgmt	For
QIAGEN NV	06/23/2022	Netherlands	Approve Cancellation of Shares	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Approve Allocation of Income, with a Final Dividend of JPY 48	Mgmt	For

Nihon Kohden Corp.	06/28/2022	Japan	Amend Articles to Disclose Shareholder Meeting Materials on Internet	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Ogino, Hirokazu	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Tamura, Takashi	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Hasegawa, Tadashi	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Hirose, Fumio	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Tanaka, Eiichi	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Yoshitake, Yasuhiro	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Satake, Hiroyuki	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Muraoka, Kanako	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director Sasaya, Hidemitsu	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director and Audit Committee Member Kawatsuhara, Shigeru	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Director and Audit Committee Member Shimizu, Kazuo	Mgmt	For
Nihon Kohden Corp.	06/28/2022	Japan	Elect Alternate Director and Audit Committee Member Moriwaki, Sumio	Mgmt	For
GSK Plc	07/06/2022	United Kingdom	Approve Matters Relating to the Demerger of Haleon Group from the GSK Group	Mgmt	For
GSK Plc	07/06/2022	United Kingdom	Approve the Related Party Transaction Arrangements	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Elect Director Emily Peterson Alva	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Elect Director Cato T. Laurencin	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Elect Director Brian P. McKeon	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Elect Director Christopher I. Wright	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their Remuneration	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Amend Omnibus Stock Plan	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Renew the Board's Authority to Issue Shares Under Irish Law	Mgmt	For
Alkermes plc	07/07/2022	Ireland	Renew the Board's Authority to Opt-Out of Statutory Pre-Emptions Rights	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Richard H. Carmona	Mgmt	For

McKesson Corporation	07/22/2022	USA	Elect Director Dominic J. Caruso	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director W. Roy Dunbar	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director James H. Hinton	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Donald R. Knauss	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Bradley E. Lerman	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Linda P. Mantia	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Maria Martinez	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Susan R. Salka	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Brian S. Tyler	Mgmt	For
McKesson Corporation	07/22/2022	USA	Elect Director Kathleen Wilson-Thompson	Mgmt	For
McKesson Corporation	07/22/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
McKesson Corporation	07/22/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
McKesson Corporation	07/22/2022	USA	Approve Omnibus Stock Plan	Mgmt	For
McKesson Corporation	07/22/2022	USA	Amend Qualified Employee Stock Purchase Plan	Mgmt	For
McKesson Corporation	07/22/2022	USA	Reduce Ownership Threshold for Shareholders to Call Special Meeting	SH	Against
McKesson Corporation	07/22/2022	USA	Adopt Policy on 10b5-1 Plans	SH	Against
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Elect Director Scott Tarriff	Mgmt	For
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Elect Director Jennifer K. Simpson	Mgmt	For
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Elect Director Luciana Borio	Mgmt	For
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Eagle Pharmaceuticals, Inc.	07/28/2022	USA	Advisory Vote on Say on Pay Frequency	Mgmt	One Year

ABIOMED, Inc.	08/10/2022	USA	Elect Director Michael R. Minogue	Mgmt	For
ABIOMED, Inc.	08/10/2022	USA	Elect Director Martin P. Sutter	Mgmt	For
ABIOMED, Inc.	08/10/2022	USA	Elect Director Paula A. Johnson	Mgmt	For
ABIOMED, Inc.	08/10/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
ABIOMED, Inc.	08/10/2022	USA	Ratify Deloitte & Touche LLP as Auditors	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Craig A. Barbarosh	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director George H. Bristol	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Darnell Dent	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Julie D. Klapstein	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Jeffrey H. Margolis	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Geraldine McGinty	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Morris Panner	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director Pamela S. Puryear	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Elect Director David Sides	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Ratify PricewaterhouseCoopers LLP as Auditors	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
NextGen Healthcare, Inc.	08/17/2022	USA	Advisory Vote on Say on Pay Frequency	Mgmt	One Year
Elekta AB	08/25/2022	Sweden	Management Proposals	Mgmt	
Elekta AB	08/25/2022	Sweden	Open Meeting	Mgmt	
Elekta AB	08/25/2022	Sweden	Elect Chairman of Meeting	Mgmt	For
Elekta AB	08/25/2022	Sweden	Prepare and Approve List of Shareholders	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Agenda of Meeting	Mgmt	For
Elekta AB	08/25/2022	Sweden	Designate Per Colleen as Inspector of Minutes of Meeting	Mgmt	For
Elekta AB	08/25/2022	Sweden	Designate Filippa Gerstadt as Inspector of Minutes of Meeting	Mgmt	For
Elekta AB	08/25/2022	Sweden	Acknowledge Proper Convening of Meeting	Mgmt	For

Elekta AB	08/25/2022	Sweden	Receive Financial Statements and Statutory Reports	Mgmt	
Elekta AB	08/25/2022	Sweden	Accept Financial Statements and Statutory Reports	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Allocation of Income and Dividends of SEK 2.40 Per Share	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member and Chair Laurent Leksell	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Caroline Leksell Cooke	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Johan Malmquist	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Wolfgang Reim	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Jan Secher	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Birgitta Stymne Goransson	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of Board Member Cecilia Wikstrom	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Discharge of President and CEO Gustaf Salford	Mgmt	For
Elekta AB	08/25/2022	Sweden	Determine Number of Members (8) of Board	Mgmt	For
Elekta AB	08/25/2022	Sweden	Determine Number Deputy Members (0) of Board	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Remuneration of Directors in the Aggregate Amount of SEK 6.02 Million	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Remuneration of Auditors	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Laurent Leksell as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Caroline Leksell Cooke as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Johan Malmquist as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Wolfgang Reim as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Jan Secher as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Birgitta Stymne Goransson as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Cecilia Wikstrom as Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Elect Kelly Lundy as New Director	Mgmt	For
Elekta AB	08/25/2022	Sweden	Reelect Laurent Leksell as Board Chair	Mgmt	For
Elekta AB	08/25/2022	Sweden	Ratify Ernst & Young as Auditors	Mgmt	For

Elekta AB	08/25/2022	Sweden	Approve Remuneration Report	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Performance Share Plan 2022	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Equity Plan Financing	Mgmt	For
Elekta AB	08/25/2022	Sweden	Approve Equity Plan Financing of 2020, 2021 and 2022 Performance Share Plans	Mgmt	For
Elekta AB	08/25/2022	Sweden	Authorize Share Repurchase Program	Mgmt	For
Elekta AB	08/25/2022	Sweden	Authorize Reissuance of Repurchased Shares	Mgmt	For
Elekta AB	08/25/2022	Sweden	Shareholder Proposal Submitted by Thorwald Arvidsson	Mgmt	
Elekta AB	08/25/2022	Sweden	Amend Articles Re: Editorial Changes	SH	Against
Elekta AB	08/25/2022	Sweden	Amend Articles Re: Governance-Related	SH	None
Elekta AB	08/25/2022	Sweden	Amend Procedures for Nomination Committee	SH	Against
Elekta AB	08/25/2022	Sweden	Instruct Board to Investigate the Conditions for the Introduction of Performance-Based Remuneration for Members of the Board	SH	Against
Elekta AB	08/25/2022	Sweden	Management Proposal	Mgmt	
Elekta AB	08/25/2022	Sweden	Close Meeting	Mgmt	
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Accept Financial Statements and Statutory Reports	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Approve Final Dividend	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Elect Yim Chun Leung as Director	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Elect Pun Yue Wai as Director	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Elect Lam Kwing Tong, Alan as Director	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Authorize Board to Fix Remuneration of Directors	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Approve KPMG as Auditors and Authorize Board to Fix Their Remuneration	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Authorize Repurchase of Issued Share Capital	Mgmt	For

Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Authorize Reissuance of Repurchased Shares	Mgmt	For
Jacobson Pharma Corporation Limited	09/23/2022	Cayman Islands	Amend Amended and Restated Memorandum and Articles of Association and Adopt Second Amended and Restated Memorandum and Articles of Association	Mgmt	For
CSL Limited	10/12/2022	Australia	Elect Marie McDonald as Director	Mgmt	For
CSL Limited	10/12/2022	Australia	Elect Megan Clark as Director	Mgmt	For
CSL Limited	10/12/2022	Australia	Approve Remuneration Report	Mgmt	For
CSL Limited	10/12/2022	Australia	Approve Grant of Performance Share Units to Paul Perreault	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Approve Financial Statements and Reports of the Directors and Auditors	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Approve Remuneration Report	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Elect Yasmin Allen as Director	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Elect Michael del Prado as Director	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Elect Karen Penrose as Director	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Approve Grant of Options and Performance Rights to Dig Howitt	Mgmt	For
Cochlear Limited	10/18/2022	Australia	Approve the Increase in Maximum Aggregate Remuneration of Non-Executive Directors	Mgmt	None
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Steven K. Barg	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Michelle M. Brennan	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Sujatha Chandrasekaran	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Carrie S. Cox	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Bruce L. Downey	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Sheri H. Edison	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director David C. Evans	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Patricia A. Hemingway Hall	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Jason M. Hollar	Mgmt	For

Cardinal Health, Inc.	11/09/2022	USA	Elect Director Akhil Johri	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Gregory B. Kenny	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Nancy Killefer	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Elect Director Christine A. Mundkur	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Ratify Ernst & Young LLP as Auditors	Mgmt	For
Cardinal Health, Inc.	11/09/2022	USA	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Richard H. Anderson	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Craig Arnold	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Scott C. Donnelly	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Lidia L. Fonseca	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Andrea J. Goldsmith	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Randall J. Hogan, III	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Kevin E. Lofton	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Geoffrey S. Martha	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Elizabeth G. Nabel	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Denise M. O'Leary	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Elect Director Kendall J. Powell	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Approve PricewaterhouseCoopers LLP as Auditors and Authorize Board to Fix Their Remuneration	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Advisory Vote to Ratify Named Executive Officers' Compensation	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Renew the Board's Authority to Issue Shares Under Irish Law	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Renew the Board's Authority to Opt-Out of Statutory Pre-Emptions Rights Under Irish Law	Mgmt	For
Medtronic Plc	12/08/2022	Ireland	Authorize Overseas Market Purchases of Ordinary Shares	Mgmt	For
El.En. SpA	12/15/2022	Italy	Ordinary Business	Mgmt	
El.En. SpA	12/15/2022	Italy	Amend Remuneration Policy	Mgmt	For
El.En. SpA	12/15/2022	Italy	Approve 2026-2031 Stock Option Plan	Mgmt	For

El.En. SpA	12/15/2022	Italy	Extraordinary Business	Mgmt	
El.En. SpA	12/15/2022	Italy	Authorize Board to Increase Capital to Service 2026-2031 Stock Option Plan	Mgmt	For
			3,126	3,126	

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)
FINANCIAL STATEMENTS
For the year ended 31 December 2022
with
Independent Auditor's Report to the Unitholders



KPMG Professional Services

Riyadh Front, Airport Road
P. O. Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Commercial Registration No. 1010425494

Headquarters in Riyadh

كي بي إم جي للاستشارات المهنية

واجهة الرياض، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

المركز الرئيسي في الرياض

Independent Auditor's Report

To the Unitholders of SNB Capital Global Healthcare Fund

Opinion

We have audited the financial statements of **SNB Capital Global Healthcare Fund** (the "Fund") managed by the **SNB Capital Company** (the "Fund Manager"), which comprise the statement of financial position as at 31 December 2022, the statements of profit or loss and other comprehensive income, changes in net assets attributable to the Unitholders and cash flows for the year then ended, and notes to the financial statements, comprising significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at 31 December 2022, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards ("IFRS") that are endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Fund in accordance with the International Code of Ethics for Professional Accountants (including International Independence Standards), that is endorsed in the Kingdom of Saudi Arabia (the "Code"), that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with the Code's requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Fund Manager and Those Charged with Governance for the Financial Statements

The Fund Manager is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS that are endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by the SOCPA, and to comply with the applicable provisions of the Investment Funds Regulations issued by the Capital Market Authority ("CMA"), the Fund's terms and conditions, and for such internal control as the Fund Manager determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Fund Manager is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Fund Manager either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, the Fund Board, are responsible for overseeing the Fund's financial reporting process.

KPMG professional Services, a professional closed joint stock company registered in the Kingdom of Saudi Arabia, With the paid-up capital of (40,000,000) SAR. (Previously known as "KPMG Al Fozan & Partners Certified Public Accountants") A non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved

كي بي إم جي للاستشارات المهنية شركة مساهمة مغلقة، مسجلة في المملكة العربية السعودية، رأس مالها (٤٠,٠٠٠,٠٠٠) ريال سعودي مدفوع بالكامل، المسماة سابقاً "شركة كي بي إم جي للقرضات وشركاء محاسبين ومراجعين قانونيين". وهي عضو غير شريك في الشبكة العالمية للشركات كي بي إم جي العالمية والتابعة لـ كي بي إم جي العالمية المحدودة، شركة تجارزة محدودة بضمان. جميع الحقوق محفوظة.



Independent Auditor's Report

To the Unitholders of SNB Capital Global Healthcare Fund (continued)

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. 'Reasonable assurance' is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund Manager's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Fund Manager.
- Conclude on the appropriateness of the Fund Manager's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, then we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit of **SNB Capital Global Healthcare Fund** (the "Fund").

KPMG Professional Services

Ebrahim Oboud Baeshen
License No. 382

Riyadh: 17 Sha'ban 1444H
Corresponding to 09 March 2023



SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

STATEMENT OF FINANCIAL POSITION

As at 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

		31 December 2022	31 December 2021
	<i>Notes</i>		
ASSETS			
Cash and cash equivalents	8	1,027	649
FVTPL investments	9	59,613	81,355
Other receivables		26	23
Total assets		60,666	82,027
LIABILITIES			
Other payables		483	255
Net assets attributable to the Unitholders		60,183	81,772
Units in issue in thousands (number)	10	18,881	22,314
Net assets value per unit (USD)		3.1876	3.6646

The accompanying notes 1 to 15 form an integral part of these financial statements

SNB CAITAL GLOBAL HEALTHCARE FUND (Managed by the SNB Capital Company)**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

	<i>Note</i>	<u>For the year ended 31 December</u>	
		<u>2022</u>	<u>2021</u>
Unrealised loss on FVTPL investments – net		(10,811)	(3,461)
Dividend income		733	671
Realised gain on sale on FVTPL investments – net		645	16,169
Total (loss) / income		(9,433)	13,379
Management fees	<i>11</i>	(1,204)	(1,417)
Value added tax expense		(180)	(213)
Administrative expenses		(16)	(17)
Custody fees		(14)	(4)
Professional fees		(10)	(10)
Shariah audit fees		(8)	(8)
Fund board remuneration		(6)	(6)
Capital Market Authority fees		(2)	(2)
Total operating expenses		(1,440)	(1,677)
(Loss) / profit for the year		(10,873)	11,702
Other comprehensive income for the year		-	-
Total comprehensive (loss) / income for the year		(10,873)	11,702

The accompanying notes 1 to 15 form an integral part of these financial statements

SNB CAITAL GLOBAL HEALTHCARE FUND (Managed by the SNB Capital Company)

STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO THE UNITHOLDERS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

	For the year ended 31 December	
	<u>2022</u>	<u>2021</u>
Net assets attributable to the Unitholders at the beginning of the year	81,772	72,587
Total comprehensive (loss) / income for the year	(10,873)	11,702
Decrease in equity from units transactions during the year		
Proceeds from units issued	2,743	8,640
Value of units redeemed	(13,459)	(11,157)
	(10,716)	(2,517)
Net assets attributable to the Unitholders at the end of the year	<u>60,183</u>	<u>81,772</u>

The accompanying notes 1 to 15 form an integral part of these financial statements

SNB CAITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

STATEMENT OF CASH FLOWS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

	<i>Notes</i>	For the year ended 31 December	
		<u>2022</u>	<u>2021</u>
Cash flows from operating activities		(10,873)	11,702
(Loss) / profit for the year			
<u>Adjustments for:</u>			
Unrealized loss on FVTPL investments – net		10,811	3,461
Realized gain on FVTPL investments – net		(645)	(16,169)
		<u>(707)</u>	<u>(1,006)</u>
<u>Net changes in operating assets and liabilities:</u>			
FVTPL investments		11,576	1,055
Other receivables		(3)	840
Other payables		228	(20)
		<u>11,094</u>	<u>869</u>
Net cash generated from operating activities			
Cash flows from financing activities			
Proceeds from units issued		2,743	8,640
Value of units redeemed		(13,459)	(11,157)
		<u>(10,716)</u>	<u>(2,517)</u>
Net cash used in financing activities			
Net increase / (decrease) in cash and cash equivalents		378	(1,648)
Cash and cash equivalents at the beginning of the year	8	<u>649</u>	<u>2,297</u>
Cash and cash equivalents at the end of the year	8	<u>1,027</u>	<u>649</u>

The accompanying notes 1 to 15 form an integral part of these financial statements

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

1. THE FUND AND ITS ACTIVITIES

SNB Capital Global Healthcare Fund (the "Fund") is a Shariah compliant, open-ended investment fund, established under article 31 of the Investment Funds Regulations, managed by SNB Capital Company, a subsidiary of the Saudi National Bank (the "Bank"), for the benefit of the Fund's Unitholders.

The Fund's investments are held by Northern Trust Corporation, a custodian appointed by the Fund Manager.

The Fund Manager has appointed an international investment house, TCW Asset Management Company, United States of America as sub-manager to the Fund. Their duties include opening separate independent investment accounts and managing the Fund assets in line with investment strategies and Shariah guidelines.

The Fund invests in securities of Shariah compliant companies involved in healthcare services and related activities, listed on major international stock exchanges. Surplus cash balances may be placed in Murabaha contracts.

The terms and conditions of the Fund were originally approved by the Saudi Central Bank (SAMA) and subsequently endorsed by CMA through its letter dated 18 Dhul Hijja 1429H (corresponding to 16 December 2008). The Fund commenced its activities on 3 Shaban 1421H (corresponding to 30 October 2000).

The Fund is governed by the Investment Funds Regulations (the "Regulations") published by Capital Market Authority ("CMA") on 3 Dhul Hijja 1427H (corresponding to 24 December 2006). The Regulations were amended (the "Amended Regulations") on 12 Rajab 1442H (corresponding to 24 February 2021).

2. BASIS OF ACCOUNTING

These financial statements of the Fund have been prepared in accordance with International Financial Reporting Standards ("IFRS") as endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA"), and comply with the applicable provisions of the Amended Regulations and the Fund's terms and conditions.

3. BASIS OF MEASUREMENT

The financial statements have been prepared on a historical cost convention using accrual basis of accounting and going concern concept except for investments measured at fair value through profit or loss ("FVTPL") which are recorded at fair value.

The Fund does not have a clearly identifiable operating cycle and therefore does not present current and non-current assets and liabilities separately in the statement of financial position. Instead, assets and liabilities are presented in order of their liquidity.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

4. FUNCTIONAL AND PRESENTATION CURRENCY

Items included in the financial statements are measured using the currency of the primary economic environment in which the Fund operates (the “functional currency”). If indicators of the primary economic environment are mixed, then Fund Manager uses judgement to determine the functional currency that most faithfully effects the economic effect of the underlying transactions, events, and conditions. The Fund’s investments transactions are denominated in US Dollar, Swiss Franc and certain other foreign currencies. Investor subscriptions and redemptions are determined based on the net assets value and received and paid in US Dollar and expenses of the Fund are also paid in US Dollar. Accordingly, Fund Manager has determined that the functional currency of the Fund is US Dollar (“USD”).

These financial statements are presented in United States Dollar (“USD”) which is the Fund’s functional and presentation currency and have been rounded off to the nearest thousand unless otherwise stated.

5. CHANGES IN FUND’S TERMS AND CONDITIONS

During the year, there have been no changes in the terms and conditions of the Fund.

6. CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimates are revised and in any future years affected.

Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

When available, the Fund measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The Fund measures instruments quoted in an active market at market price, because this price is assessed to be a reasonable approximation of the exit price.

If there is no quoted price in an active market, then the Fund uses valuation techniques that maximise the use of relevant observable inputs and minimise the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. The Fund recognizes transfer between levels of fair value at the end of the reporting period during which the change has occurred.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

6. CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS (CONTINUED)

The fair value hierarchy has the following levels:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: unobservable inputs for the asset or liability.

The Fund has classified the investments measured at FVTPL as per the fair value hierarchy as level 1. During the year, there has been no transfer in fair value hierarchy for FVTPL investments. For other financial assets and liabilities not measured at fair value such as cash and cash equivalents, other receivables and other payables, the carrying values were determined to be a reasonable approximation of fair value due to their short-term nature. The Fund has classified cash and cash equivalents as level 1 while remaining financial assets and liabilities are classified as level 3 as per the fair value hierarchy.

7. SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented.

7.1 *Cash and cash equivalents*

Cash and cash equivalents include cash at bank and short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value. Cash and cash equivalents include bank balances.

7.2 *Financial assets and liabilities*

Classification of financial assets

On initial recognition, a financial asset is measured at its fair value and classified at amortised cost, fair value through other comprehensive income ("FVOCI") or fair value through profit or loss ("FVTPL").

Financial assets measured at amortised cost

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as measured at FVTPL:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and commission on the principal amount outstanding.

Financial assets measured at FVOCI

A financial asset is measured at FVOCI only if it meets both of the following conditions and is not designated as measured at FVTPL.

- it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and commission on the principal amount outstanding.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.2 *Financial assets and liabilities (continued)*

Classification of financial assets (continued)

Financial assets measured at FVOCI (continued)

On initial recognition of an equity investment that is not held for trading, the Fund Manager may irrevocably elect to present subsequent changes in fair value in OCI. This election is made on an investment-by-investment basis.

Financial assets measured at FVTPL

All financial assets not classified as measured at amortised cost or FVOCI are measured at FVTPL.

Business model assessment

The Fund Manager assesses the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice;
- how the performance of the portfolio is evaluated and reported to the Fund Manager;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – for example, whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectations about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of how the Fund's stated objective for managing the financial assets is achieved and how cash flows are realized.

The business model assessment is based on reasonably expected scenarios without taking 'worst case' or 'stress case' scenarios into account. If cash flows after initial recognition are realized in a way that is different from the Fund's original expectations, the Fund does not change the classification of the remaining financial assets held in that business model, but incorporates such information when assessing newly purchased financial assets going forward.

Financial assets that are held for trading and whose performance is evaluated on a fair value basis are measured at FVTPL because they are neither held to collect contractual cash flows nor held both to collect contractual cash flows and to sell financial assets.

Assessment whether contractual cash flows are solely payments of principal and commission

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. Interest or 'commission' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (for example, liquidity risk and administrative costs), as well as profit margin.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.2 *Financial assets and liabilities (continued)*

Assessment whether contractual cash flows are solely payments of principal and commission (continued)

In assessing whether the contractual cash flows are solely payments of principal and commission, the Fund considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making the assessment, the Fund considers:

- contingent events that would change the amount and timing of cash flows;
- leverage features;
- prepayment and extension terms;
- terms that limit the Fund's claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and
- features that modify consideration of the time value of money – e.g. periodical reset of interest / commission rates.

Reclassifications

Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Fund changes its business model for managing financial assets.

Classification of financial liabilities

The Fund classifies its financial liabilities at amortised cost unless it has designated liabilities at FVTPL.

Recognition and initial measurement

Financial assets and liabilities measured at FVTPL are initially recognized on the trade date, which is the date on which the Fund becomes a party to the contractual provisions of the instrument. The Fund shall recognise a financial asset or a financial liability in its statement of financial position when, and only when, the entity becomes party to the contractual provisions of the instrument. Other financial assets and financial liabilities are recognized on the date on which they are originated.

A financial asset or financial liability is measured initially at fair value plus or minus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition issue.

Subsequent measurement

Financial assets measured at FVTPL are subsequently measured at fair value. Net gain or losses including any foreign exchange gains and losses, are recognized in profit or loss in 'realized and unrealized gain / (loss) on FVTPL investments – net' in the statement of profit or loss and other comprehensive income.

Financial assets and financial liabilities at amortised cost are subsequently measured at amortised cost using the effective interest / commission method and is recognized in the statement of profit or loss and other comprehensive income. Any gain or loss on de-recognition is also recognized in the statement of profit or loss and other comprehensive income. The 'amortised cost' of a financial asset or financial liability is the amount at which the financial asset or financial liability is measured on initial recognition minus the principal repayments, plus or minus the cumulative interest / commission using the effective interest / commission method of any difference between that initial amount and the maturity amount and, for financial assets, adjusted for any expected credit loss allowance.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.2 *Financial assets and liabilities (continued)*

Derecognition

The Fund derecognizes a financial asset when the contractual rights to the cash flow from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Fund neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

On derecognition of the financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset that is derecognised) and the consideration received (including any new asset obtained less any new liability assumed) is recognized in the statement of profit or loss and other comprehensive income. Any commission in such transferred financial assets that is created or retained by the Fund is recognized as a separate asset or liability.

The Fund enters into transactions whereby it transfers assets recognized on its statement of financial position but retains either all or substantially all of the risks and rewards of the transferred assets or a portion of them. If all or substantially all of the risk and rewards are retained, then the transferred assets are not derecognized. The Fund derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire.

Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Fund has a legally enforceable right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle their liability simultaneously.

Income and expenses are presented on a net basis for gain and losses from financial instruments at FVTPL and foreign exchange gains and losses.

7.3 *Provisions*

A provision is recognised when the Fund has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount can be made. Provisions are not recognised for future operating losses.

7.4 *Net assets value per unit*

The net assets value per unit is calculated by dividing the net assets attributable to the Unitholders included in the statement of financial position by the number of units outstanding at the year end.

7.5 *Units in issue*

The Fund classifies financial instruments issued as financial liabilities or equity instruments in accordance with the substance of the contractual terms of the instruments.

The Fund has redeemable units in issue. On liquidation of the Fund, they entitle the holders to the residual net assets. They rank pari passu in all respects and have identical terms and conditions. The redeemable units provide investors with the right to require redemption for cash at a value proportionate to the investor's share in the Fund's net assets at each redemption date as well as in the event of the Fund's liquidation.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.5 *Units in issue (continued)*

Redeemable units are classified as equity as these meets all of the following conditions:

- they entitle the holder to a pro rata share of the Fund's net assets in the event of the Fund's liquidation;
- they are in the class of instruments that are subordinate to all other classes of instruments;
- all financial instruments in the class of instruments that are subordinate to all other classes of instruments have identical features;
- the instruments do not include any other features that would require classification as a liability; and
- the total expected cash flows attributable to the instruments over their life are based substantially on the profit or loss, the change in recognized net assets or the change in the fair value of the recognized and unrecognized net assets of the Fund over the life of the instrument.

Incremental costs directly attributable to the issue or redemption of redeemable units are recognized directly in net assets as a deduction from the proceeds or part of the acquisition cost.

7.6 *Taxation / Zakat*

Under the current system of Zakat and income tax in the Kingdom of Saudi Arabia, the Fund is exempt from paying any Zakat and income tax. Zakat and income tax are considered to be the obligation of the Unitholders and are not provided in the financial statements.

The value added tax ("VAT") applicable for fees and expenses are recognized in the statement of comprehensive income.

7.7 *Dividend income*

Dividend income is recognized in the statement of profit or loss and other comprehensive income on the date on which the right to receive payment is established. For quoted equity securities, this is usually the ex-dividend date. For unquoted equity securities, this is usually the date on which the shareholders approve the payment of dividend. Dividend income from equity securities designated at FVTPL is recognized in statement of profit or loss and other comprehensive income in a separate line item.

7.8 *Management fees expense*

Management fees expense is recognized in the statement of profit or loss and other comprehensive income as the related services are performed.

7.9 *Accrued expenses and other payables*

Accrued expenses and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective commission method.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

7. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

7.10 *New standards, interpretations and amendments thereof, adopted by the Fund*

Below amendments to accounting standards, interpretations and amendments became applicable for annual reporting periods commencing on or after 1 January 2022. The Fund manager has assessed that the amendments have no significant impact on the Fund's financial statements.

Standards, interpretations and amendments

COVID-19-Related Rent Concessions beyond 30 June 2021 – Amendment to IFRS 16
Amendments to IAS 37 - Onerous Contracts – Cost of Fulfilling a Contract
Annual Improvements to IFRS Standards 2018-2020
Reference to the Conceptual Framework (Amendments to IFRS 3)
Property, Plant and Equipment: Proceeds before Intended Use (Amendments to IAS 16)

7.11 *Standards, interpretations and amendments issued but not yet effective*

Standards, interpretations and amendments issued but not yet effective are listed below. The Fund intends to adopt these standards when they become effective.

<u>Standards, interpretations and amendments</u>	<u>Description</u>	<u>Effective from periods beginning on or after the following date</u>
Amendments to IAS 1 and IFRS practice statement 2	Disclosure of accounting policies	1 January 2023
Amendments to IAS 8	Definition of accounting estimates	1 January 2023
Amendments to IAS 12	Deferred tax related to assets and liabilities arising from a single transaction	1 January 2023
Amendments to IFRS 17	Insurance Contracts	1 January 2023
Amendments to IFRS 16	Lease Liability in a Sale and Leaseback Transaction	1 January 2024
Amendments to IAS 1	Classification of liabilities as current or non-current	1 January 2024
Amendments to IFRS 10 and IAS 28	Sale or contribution of assets between investor or Joint Venture	Available for optional adoption / effective date deferred indefinitely

The above standards, interpretations and amendments are not expected to have a significant impact on the Fund's financial statements.

8. CASH AND CASH EQUIVALENTS

This comprises of balances held with an international bank having sound credit rating.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

9. FVTPL NVESTMENTS

The composition of equity investments measured at FVTPL by currency is summarized below:

		31 December 2022		
<u>Currency</u>	<u>Country</u>	<u>% of total investments (fair value)</u>	<u>Cost</u>	<u>Fair value</u>
United States Dollar	United States of America and Ireland	62.48	31,516	37,248
Swiss Franc	Switzerland	13.77	7,975	8,209
Euro	Denmark, France, Germany, Luxembourg and Netherlands	10.23	5,564	6,097
Danish Krone	Denmark	8.47	3,545	5,049
Australian Dollar	Australia	1.81	1,072	1,081
Others	United Kingdom, Sweden, Japan, Norway, Cayman Islands and Singapore	3.24	1,406	1,929
		100	51,078	59,613

		31 December 2021		
<u>Currency</u>	<u>Country</u>	<u>% of total investments (fair value)</u>	<u>Cost</u>	<u>Fair value</u>
United States Dollar	United States of America and Ireland	62.27	36,976	50,657
Swiss Franc	Switzerland	14.51	9,014	11,806
Euro	Denmark, France, Germany, Luxembourg and Netherlands	9.36	6,282	7,619
Danish Krone	Denmark	8.37	5,895	6,808
Australian Dollar	Australia	1.67	1,121	1,363
Others	United Kingdom, Sweden, Japan, Norway, and Singapore	3.82	2,721	3,102
		100	62,009	81,355

10. UNITS TRANSACTIONS

Transactions in units during the year are summarized as follows:

	For the year ended 31 December	
	2022	2021
	Units in '000	Units in '000
Units at the beginning of the year	22,314	23,042
Units issued	867	2,601
Units redeemed	(4,300)	(3,329)
Net decrease in units	(3,433)	(728)
Units at the end of the year	18,881	22,314

As at 31 December 2022, the top five Unitholders represented 68.90% (2021: 66.56%) of the Fund's units.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

11. RELATED PARTY TRANSACTIONS AND BALANCES

The related parties of the Fund include the Fund Manager, the Fund Board, other funds managed by the Fund Manager, and the Saudi National Bank, being parent of the Fund Manager.

Management fees and other expenses

The Fund is managed and administered by the Fund Manager. For these services, the Fund accrues, daily a management fee, as determined by the Fund Manager, up to a maximum of 1.85% (2021: 1.85%) per annum of the Fund's daily net assets as set out in the Fund's terms and conditions.

The Fund Manager is also entitled to recover expenses incurred on behalf of the Fund relating to audit, custody, advisory, data processing and other similar charges. The maximum amount of such expenses that can be recovered from the Fund by the Fund Manager is restricted to 0.5% (2021: 0.5%) per annum of the Fund's net assets at the respective valuation days. These expenses are recovered by the Fund Manager on an actual basis.

Following are the details of transactions and balances with Fund Manager related to management fees and other expenses:

<u>Related party</u>	<u>Nature of transactions</u>	<u>Amounts of transactions for the year ended 31 December</u>		<u>Payable as at 31 December</u>	
		<u>2022</u>	<u>2021</u>	<u>2022</u>	<u>2021</u>
SNB Capital Company	Management fees	1,204	1,417	326	170
	Expenses paid on behalf of the Fund	236	260	49	9
The Fund Board	Fund Board remuneration	6	6	7	1

12. FINANCIAL RISK MANAGEMENT

12.1 Financial risk factors

The Fund's activities expose it to a variety of financial risks including market risk, credit risk, liquidity risk and operational risk.

The Fund Manager is responsible for identifying and controlling risks. The Fund Board supervises the Fund Manager and is ultimately responsible for the overall management of the Fund.

Monitoring and controlling risks are primarily set up to be performed based on the limits established in the terms and conditions document which sets out the Fund's overall business strategies, tolerance of risks and general risk management philosophy. In accordance with the terms and conditions of the Fund, the Fund Manager is obliged to take actions to re-balance the portfolio in line with the investment guidelines when needed.

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

12. FINANCIAL RISK MANAGEMENT (CONTINUED)

12.1 Financial risk factors (continued)

12.1.1 Market risk

'Market Risk' is the risk that changes in market prices – such as commission rates, foreign exchange rates, equity prices and credit spreads – will affect the Fund's income or the fair value of its holdings in financial instruments.

a) Foreign exchange risk

Foreign exchange risk is the risk that the value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates and arises from financial instruments denominated in foreign currencies.

The Fund's financial assets and liabilities are denominated in currencies other than its functional currency. Accordingly, the value of the Fund's assets may be affected favorably or adversely by fluctuations in other currency rates.

The effect on net assets of a reasonably possible notional movement of the US Dollar against the underlying currencies of the financial assets held in foreign currencies with all other variables held constant is as follows:

	Change in currency rates	31 December 2022	31 December 2021
Swiss Franc	± 10%	± 822	± 1,181
Euro	± 10%	± 610	± 762
Danish Krone	± 10%	± 505	± 681
Australian Dollar	± 10%	± 112	± 136
Others	± 10%	± 193	± 310

b) Commission rate risk

Commission rate risk is the risk that the value of the future cash flows of a financial instrument or fair values of fixed coupon financial instruments will fluctuate due to changes in market commission rates.

All the assets and liabilities of the Fund are non-commission bearing therefore the Fund is not exposed to commission rate risk.

c) Other price risk

Other price risk is the risk that the value of the Fund's financial instruments will fluctuate as a result of changes in market prices caused by factors other than foreign currency and commission rate movements. Other price risk arises primarily from uncertainty about the future prices of financial instruments that the Fund holds. The Fund Manager daily monitors concentration of risk in equity based on company and industries in line with defined limits while closely tracking the portfolio level volatilities. As of the statement of financial position date, the Fund has investments in quoted equity securities which are exposed to other price risk.

The effect on net assets attributable to the Unitholders (as a result of the change in the fair value of investments) as at 31 December due to a reasonably possible notional change in market value of 10% in the value of investments, with all other variables held constants, is as follows:

	31 December 2022	31 December 2021
Effect on net assets attributable to the Unitholders	± 5,961	± 8,136

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

12. FINANCIAL RISK MANAGEMENT (CONTINUED)

12.1 Financial risk factors (continued)

12.1.2 Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge their obligation and cause the other party to incur a financial loss. The Fund Manager seeks to manage credit risk by monitoring credit exposures, limiting transactions with specific counterparties, and continually assessing the creditworthiness of counterparties.

As at the statement of financial position date, the Fund's significant exposure to credit risk is cash and cash equivalents, which represents cash at bank with an international bank having Moody's credit rating of A3 which is in line with globally understood definition of investment grade. Accordingly, there is no impact of expected credit loss on these financial assets.

12.1.3 Liquidity risk

Liquidity risk is the risk that the Fund may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can only do so on terms that are materially disadvantageous.

The Fund's terms and conditions provide for subscription and redemption of units on every US and Saudi Business Day (Monday to Thursday), and it is, therefore, exposed to the liquidity risk of not being able to meet the Unitholder redemption requests on these days. The Fund Manager monitors liquidity requirements by ensuring that sufficient funds are available to meet any commitments as they arise, either through new subscriptions, liquidation of the investment portfolio or by taking short term loans from the facilities obtained by the Fund Manager.

The Fund manages its liquidity risk by investing predominantly in securities that it expects to be able to liquidate within short period.

12.1.4 Operational risk

Operational risk is the risk of direct or indirect loss arising from a variety of causes associated with the processes, technology and infrastructure supporting the Fund's activities either internally or externally at the Fund's service provider and from external factors other than credit, liquidity, currency and market risks such as those arising from the legal and regulatory requirements.

The Fund's objective is to manage operational risk to balance limiting of financial losses and damage to its reputation with achieving its investment objective of maximising returns to the Unitholders.

The primary responsibility for the development and implementation of control over operational risks rests with the Risk Management Team. This responsibility is supported by the development of overall standard for the management of operational risk, which encompasses the controls and processes at the service providers and the establishment of service levels with the service providers, in the following areas:

SNB CAPITAL GLOBAL HEALTHCARE FUND
(Managed by the SNB Capital Company)

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 31 December 2022

Expressed in US Dollars '000 (unless otherwise stated)

12. FINANCIAL RISK MANAGEMENT (CONTINUED)

12.1 Financial risk factors (continued)

12.1.4 Operational risk (continued)

- documentation of controls and procedures;
- requirements for:
 - appropriate segregation of duties between various functions, roles and responsibilities;
 - reconciliation and monitoring of transactions; and
 - periodic assessment of operational risks faced.
- the adequacy of controls and procedures to address the risks identified;
- compliance with regulatory and other legal requirements;
- development of contingency plans;
- training and professional development;
- ethical and business standards; and
- risk mitigation.

13. LAST VALUATION DAY

The last valuation of day was 30 December 2022 (2021: 30 December 2021).

14. EVENTS AFTER THE END OF THE REPORTING PERIOD

There was no event subsequent to the statement of financial position date which required adjustment of or disclosure in the financial statements or notes thereto.

15. APPROVAL OF THE FINANCIAL STATEMENTS

These financial statements were approved by the Fund Board on 16 Sha'ban 1444H corresponding to 08 March 2023.